USRE42353E1 - Quinazoline derivatives and pharmaceutical compositions containing them - Google Patents
Quinazoline derivatives and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- USRE42353E1 USRE42353E1 US12/170,027 US17002797A USRE42353E US RE42353 E1 USRE42353 E1 US RE42353E1 US 17002797 A US17002797 A US 17002797A US RE42353 E USRE42353 E US RE42353E
- Authority
- US
- United States
- Prior art keywords
- alkyl
- carbamoyl
- group
- hydroxy
- fluoroanilino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 0 CC.[1*]C1=C([2*])C2=C(NC3=CC=CC=C3)N=CN=C2C=C1C[4*] Chemical compound CC.[1*]C1=C([2*])C2=C(NC3=CC=CC=C3)N=CN=C2C=C1C[4*] 0.000 description 34
- UXKBOJIJNWAHSJ-UHFFFAOYSA-N CC1=CC(C)=C(C)C(C)=C1C(C)(C)C Chemical compound CC1=CC(C)=C(C)C(C)=C1C(C)(C)C UXKBOJIJNWAHSJ-UHFFFAOYSA-N 0.000 description 3
- OFVHUALAYNDQRX-UHFFFAOYSA-N CC.CC(C)(C)C1=CC=CC=C1 Chemical compound CC.CC(C)(C)C1=CC=CC=C1 OFVHUALAYNDQRX-UHFFFAOYSA-N 0.000 description 2
- RHPMYOUWNTVRMJ-UHFFFAOYSA-N CC.NC1=CC=CC=C1 Chemical compound CC.NC1=CC=CC=C1 RHPMYOUWNTVRMJ-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- DMGRDLINYZGKSU-UHFFFAOYSA-N CC.CC.NC1=CC=CC=C1 Chemical compound CC.CC.NC1=CC=CC=C1 DMGRDLINYZGKSU-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Nc1ccccc1 Chemical compound Nc1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/023—Adhesive plasters or dressings wound covering film layers without a fluid handling layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
- A61F2013/00221—Wound bandages not adhering to the wound biodegradable, non-irritating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/84—Accessories, not otherwise provided for, for absorbent pads
- A61F13/8405—Additives, e.g. for odour, disinfectant or pH control
- A61F2013/8408—Additives, e.g. for odour, disinfectant or pH control with odour control
Definitions
- the present invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, to their use as medicaments and to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans.
- Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function.
- Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folknan, 1995, Nature Medicine 1: 27-31).
- vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan-Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324).
- Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (VEGF).
- aFGF & bFGF acidic and basic fibroblast growth factors
- VEGF vascular endothelial growth factor
- VEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024).
- Antagonism of VEGF action by sequestration of VEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844).
- Receptor tyrosine kinases are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified.
- Flt or Flt1 the fms-like tyrosine kinase receptor
- KDR the kinase insert domain-containing receptor
- Flt4 another fms-like tyrosine kinase receptor
- Two of these related RTKs, Flt and KDR have been shown to bind VEGF with high affinity (De Vries et al, 1992, Science 255: 989-991; Terman et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187: 1579-1586). Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.
- European Patent Publication No. 0326330 discloses certain quinoline, quinazoline and cinnoline plant fungicides. Certain of these plant fungicides are also stated to possess insecticidal and miticidal activity. There is however no disclosure or any suggestion that any of the compounds disclosed may be used for any purpose in animals such as humans. In particular, the European Patent Publication contains no teaching whatsoever concerning angiogenesis and/or increased vascular permeability mediated by growth factors such as VEGF.
- EP 0566226 discloses anilinoquinazolines which have activity against epidermal growth factor (EGF) receptor tyrosine kinase.
- EP 0566226 contains no teaching whatsoever concerning angiogenesis and/or increased vascular permeability mediated by growth factors such as VEGF.
- compounds of EP 0566226 which have been tested do not show significant activity against VEGF receptor tyrosine kinase.
- the present invention is based on the surprising discovery that certain quinazolines inhibit the effects of VEGF, a property of value in the treatment of disease states associated with angiogenesis and/or increased vascular permeability such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation.
- Compounds of the present invention possess good activity against VEGF receptor tyrosine kinase whilst possessing some activity against EGF receptor tyrosine kinase.
- some compounds of the present invention possess substantially higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase.
- certain compounds of the invention which have been tested possess activity against VEGF receptor tyrosine kinase such that they may be used in an amount sufficient to inhibit VEGF receptor tyrosine kinase whilst demonstrating no significant activity against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase. While we do not wish to be bound by theoretical considerations such compounds may for example be of interest in treating tumours which are associated with VEGF, especially those tumours which are dependent on VEGF for their growth.
- VEGF and EGF receptor tyrosine kinases possess good activity against both VEGF and EGF receptor tyrosine kinases. Indeed certain compounds possess substantially equivalent activities against VEGF and EGF receptor tyrosine kinases. It is believed that these compounds may be of interest in treating tumour states associated with both VEGF and EGF, especially where a patient is suffering from a condition in which tumours are present which are dependent on both VEGF and EGF for their growth.
- n 2
- R 1 is advantageously hydrogen, liydroxy, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy or amino.
- R 1 is preferably hydrogen, hydroxy, cyano, nitro, trifluoromethyl, methyl, ethyl, methoxy or ethoxy, more preferably hydrogen, methyl or methoxy, most preferably hydrogen or methoxy, but especially methoxy.
- R 2 is preferably hydrogen, fluoro, amino or nitro, but especially hydrogen.
- R 3 represents hydroxy, halogeno, C 1-2 alkyl, C 1-2 alkoxy, trifluoromethyl, cyano, amino or nitro.
- one R 3 substituent is metahydroxy and the other one is selected from halogeno and methyl.
- phenyl group bearing (R 3 ) m is preferably of the formula II:
- the phenyl group bearing (R 3 ) m is the 3-hydroxy-4-methylphenyl group, the 2-fluoro-5-hydroxyphenyl group or the 4-chloro-2-fluorophenyl group, or the 4-bromo-2-fluorophenyl group, especially the 4-chloro-2-fluorophenyl group or the 4-bromo-2-fluorophenyl group more especially the 4-chloro-2-fluorophenyl group.
- X 1 represents —O—, —S—, —NR 7 CO—, —NR 10 SO 2 — or —NR 11 — (wherein R 7 , R 10 and R 11 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- X 1 represents —O—, —S—, —NR 7 CO— or —NR 10 SO 2 — (wherein R 7 and R 10 each independently represents hydrogen or C 1-2 alkyl).
- X 1 represents —O—, —S—, —NR 7 CO— (wherein R 7 represents hydrogen or methyl).
- R 7 represents hydrogen or methyl.
- X 1 represents —O—, or —NHCO—, or —S—, especially —O—, or —S— more especially —O—.
- X 2 and X 3 which may be the same or different each represents —O—, —S—, —SO—, —SO 2 —, —NR 17 CO—, or —NR 21 — (wherein R 17 and R 21 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- X 2 and X 3 which may be the same or different each represents —O—, —S—, —SO—, —SO 2 — or —NR 21 — (wherein R 21 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- X 2 and X 3 which may be the same or different each represents —O—, —S— or —NR 21 — (wherein R 21 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- X 3 is —O— and X 2 is —NR 17 CO— (wherein R 17 represents hydrogen, or methyl).
- X 4 represents —O— or —NR 23 — (wherein R 23 represents hydrogen, C 1-3 alkyl or C 1-2 alkoxyethyl).
- X 5 represents —O—, —S—, —SO—, —SO 2 —, —NR 28 CO—, —NR 31 SO 2 — or —NR 32 — (wherein R 28 , R 31 and R 32 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl) or X 5 is carbonyl.
- X 5 represents —O—, —S—, —SO—, —SO 2 — or —NR 32 — (wherein R 32 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- X 5 represents —O— or —NR 32 — (wherein R 32 represents hydrogen or C 1-2 alkyl).
- X 6 represents —O—, —S—, —SO—, —SO 2 —, —NR 34 CO—, —NR 37 SO 2 — or —NR 38 — (wherein R 34 , R 37 and R 38 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- X 6 represents —O—.
- R 4 is selected from one of the following eight groups:
- R 4 is C 2-3 alkylX 2 methylX 3 R 16 (wherein X 2 and X 3 are as defined hereinbefore and R 16 represents hydrogen or C 1-3 alkyl) with the proviso that X 1 cannot be —CH 2 — when R 4 is C 2-3 alkylX 2 methylX 3 R 16 .
- R 4 is selected from one of the following seven groups:
- R 4 is C 2-3 alkylX 2 methylX 3 R 16 (wherein X 2 and X 3 are as defined hereinbefore and R 16 represents hydrogen or C 1-3 alkyl) with the proviso that X 1 cannot be —CH 2 — when R 4 is C 2-3 alkyX 2 xmethylX 3 R 16 .
- R 4 is selected from one of the following seven groups:
- R 4 is C 2-3 alkylX 2 methylX 3 R 16 (wherein X 2 and X 3 are as defined hereinbefore and R 16 represents hydrogen or C 1-3 alkyl) with the proviso that X 1 cannot be —CH 2 — when R 4 is C 2-3 alkylX 2 methylX 3 R 16 .
- R 4 is selected from one of the following five groups:
- R 4 is C 2-3 alkylX 2 methylX 3 R 16 (wherein X 2 and X 3 are as defined hereinbefore and R 16 represents hydrogen or C 1-3 alkyl) with the proviso that X 1 cannot be —CH 2 — when R 4 is C 2-3 alkylX 2 methylX 3 R 16 .
- R 4 is selected from one of the following five groups:
- R 4 is C 2-3 alkylX 2 methylX 3 R 16 (wherein X 2 and X 3 are as defined hereinbefore and R 16 represents hydrogen or C 1-3 alkyl) with the proviso that X 1 cannot be —CH 2 — when R 4 is C 2-3 alkylX 2 methylX 3 R 16 .
- Especially preferred values for the group R 4 -X 1 are 3-(methylsulphonyl)propoxy, (1-methylpiperidin-3-yl)methoxy, 4-(pyrrolidin-1-yl)but-2-en-1-yloxy, 2-(2-methoxyethoxy)ethoxy, 3-(1,1-dioxothiomorpholino)propoxy, 2-(2-(pyrrolidin-1-yl)ethoxy)ethoxy, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy, 3-morpholinopropylthio, 2-([N-methoxyacetyl-N-methyl]amino)ethoxy, 2-(2-oxopyrrolidin-1-yl)ethoxy, 2-thiomorpholinoethoxy, 3-(2-carbamoylpyrrolidin-1-yl)propoxy, 3-(2-oxopyrrolidin-1-yl)propoxy and 2-(2-morpholinoethoxy)eth
- More especially preferred values for the group R 4 -X 1 are 3-(methylsulphonyl)propoxy, (1-methylpiperidin-3-yl)methoxy and 4-(pyrrolidin-1-yl)but-2-en-1-yloxy.
- Preferred compounds of the present invention by virtue of their substantially equivalent activity against VEGF and EGF receptor tyrosine kinases include:
- More preferred compounds of the present invention by virtue of their substantially equivalent activity against VEGF and EGF receptor tyrosine kinases include:
- Particularly preferred compounds of the present invention by virtue of their substantially equivalent activity against VEGF and EGF receptor tyrosine kinases include:
- Additional particularly preferred compounds of the present invention by virtue of their substantially equivalent activity against VEGF and EGF receptor tyrosine kinases include:
- VEGF and EGF receptor tyrosine kinases include:
- preferred compounds are:
- alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only. An analogous convention applies to other generic terms. Unless otherwise stated the term “alkyl” advantageously refers to chains with 1-6 carbon atoms, preferably 1-4 carbon atoms.
- alkoxy as used herein, unless stated otherwise includes “alkyl” —O— groups in which “alkyl” is as hereinbefore defined.
- aryl as used herein unless stated otherwise includes reference to a C 6-10 aryl group which may, if desired, carry one or more substituents selected from halogeno, alkyl, alkoxy, nitro, trifluoromethyl and cyano, (wherein alkyl and alkoxy are as hereinbefore defined).
- aryloxy as used herein unless otherwise stated includes “aryl” —O—groups in which “aryl” is as hereinbefore defined.
- sulphonyloxy as used herein refers to alkylsulphonyloxy and arylsulphonyloxy groups in which “alkyl” and “aryl” are as hereinbefore defined.
- alkanoyl as used herein unless otherwise stated includes formyl and alkylC ⁇ O groups in which “alkyl” is as defined hereinbefore, for example C 2 alkanoyl is ethanoyl and refers to CH 3 C ⁇ O, C 1 alkanoyl is formyl and refers to CHO.
- alkenyl includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl are specific for the straight chain version only. Unless otherwise stated the term “alkenyl” advantageously refers to chains with 2-5 carbon atoms, preferably 3-5 carbon atoms.
- alkynyl includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butynyl are specific for the straight chain version only. Unless otherwise stated the term “alkynyl” advantageously refers to chains with 2-5 carbon atoms, preferably 3-5 carbon atoms.
- a compound of the formula I or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits VEGF receptor tyrosine kinase activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
- X 1 is, for example, a group of formula —NR 7 CO—, it is the nitrogen atom bearing the R 7 group which is attached to the quinazoline ring and the carbonyl (CO) group is attached to R 4
- X 1 is, for example, a group of formula —CONR 8 —
- X 1 linking groups such as —NR 10 SO 2 — and —SO 2 NR 9 —.
- R 4 is, for example, a group of the formula C 1-5 alkylX 5 R 27 and X 5 is a group —NR 28 CO—, it is the nitrogen atom bearing the R 28 group which is attached to the alkyl chain which is attached to the quinazoline ring and the carbonyl (CO) group is attached to R 27
- X 5 is, for example, a group of formula —CONR 29 —, it is the carbonyl group which is attached to the alkyl chain which is attached to the quinazoline ring and the nitrogen atom bearing the R 29 group is attached to R 27 .
- X 1 represents —NR 11 — and R 11 is C 1-3 alkoxyC 2-3 alkyl it is the C 2-3 alkyl moiety which is linked to the nitrogen atom of X 1 and an analogous convention applies to other groups.
- R 4 is, for example, a group of formula C 1-5 alkylX 2 C 1-5 alkylX 3 R 16 , it is the terminal C 1-5 alkyl moiety which is bound to X 1
- R 4 is, for example, a group of formula C 2-5 alkenylR 14 it is the C 2-5 alkenyl moiety which is bound to X 1 and an analgous convention applies to other groups.
- R 4 is a group 1-R 33 prop-1-en-3-yl it is the first carbon to which the group R 33 is attached and it is the third carbon which is linked to X 1
- R 4 is a group 2-R 33 pent-3-en-5-yl it is the second carbon to which the group R 33 is attached and it is the fifth carbon which is linked to X 1
- an analogous convention applies to other groups.
- the present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts thereof.
- Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I and their pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula I as hereinbefore defined which are sufficiently basic to form such salts.
- Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid.
- salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation.
- Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- a compound of the formula I, or salt thereof, and other compounds of the invention may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes include, for example, those illustrated in European Patent Applications, Publication Nos. 0520722, 0566226, 0602851 and 0635498. Such processes, are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
- the reaction is advantageously effected in the presence of either an acid or a base.
- an acid is, for example, an anhydrous inorganic acid such as hydrogen chloride.
- a base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or for example, an alkali metal or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
- such a base is, for example, an alkali metal hydride, for example sodium hydride, or an alkali metal or alkaline earth metal amide, for example sodium amide or sodium bis(trimethylsilyl)amide.
- the reaction is preferably effected in the presence of an inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, 2-propanol or ethyl acetate, a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide.
- the reaction is conveniently effected at a temperature in the range, for
- the compound of the invention may be obtained from this process in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H-L 1 wherein L 1 has the meaning defined hereinbefore.
- the salt may be treated with a base as defined hereinbefore using a conventional procedure.
- halogenating agents include inorganic acid halides, for example thionyl chloride, phosphorus(III)chloride, phosphorus(V)oxychloride and phosphorus(V)chloride.
- the halogenation reaction is conveniently effected in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, or an aromatic hydrocarbon solvent such as benzene or toluene.
- the reaction is conveniently effected at a temperature in the range, for example 10 to 150° C., preferably in the range 40 to 100° C.
- the compounds of formula XII and salts thereof which constitute a further feature of the present invention may for example be prepared by reacting a compound of the formula XIII:
- the compounds of formula XII and salts thereof may also be prepared by cyclising a compound of the formula XIV:
- the compounds of formula III and salts thereof may also be prepared for example by reacting a compound of the formula XVIII:
- a compound of formula XVIII is conveniently used in which L 2 represents a phenoxy group which may if desired carry up to 5 substituents, preferably up to 2 substituents, selected from halogeno, nitro and cyano.
- the reaction may be conveniently effected under conditions as described for process (c) hereinbefore.
- One compound of formula III may if desired be converted into another compound of formula III in which the moiety L 1 is different.
- a compound of formula III in which L 1 is other than halogeno, for example optionally substituted phenoxy may be converted to a compound of formula III in which L 1 is halogeno by hydrolysis of a compound of formula III (in which L 1 is other than halogeno) to yield a compound of formula XII as hereinbefore defined, followed by introduction of halide to the compound of formula XII, thus obtained as hereinbefore defined, to yield a compound of formula III in which L 1 represents halogen.
- the compounds of formula V and salts thereof may also be prepared by reacting a compound of formula XXI:
- the compounds of formula V and salts thereof may also be prepared by reacting a compound of formula XXII:
- a pharmaceutically acceptable salt of a compound of the formula I When a pharmaceutically acceptable salt of a compound of the formula I is required, it may be obtained, for example, by reaction of said compound with, for example, an acid using a conventional procedure, the acid having a pharmaceutically acceptable anion.
- This assay determines the ability of a test compound to inhibit tyrosine kinase activity.
- DNA encoding VEGF or epidermal growth factor (EGF) receptor cytoplasmic domains may be obtained by total gene synthesis (Edwards M, International Biotechnology Lab 5(3), 19-25, 1987) or by cloning. These may then be expressed in a suitable expression system to obtain polypeptide with tyrosine kinase activity.
- EGF and EGF receptor cytoplasmic domains which were obtained by expression of recombinant protein in insect cells, were found to display intrinsic tyrosine kinase activity.
- VEGF receptor Flt (Genbank accession number X51602)
- a 1.7 kb DNA fragment encoding most of the cytoplasmic domain, commencing with methionine 783 and including the termination codon, described by Shibuya et al (Oncogene, 1990, 5: 519-524) was isolated from cDNA and cloned into a baculovirus transplacement vector (for example pAcYM1 (see The Baculovirus Expression System: A Laboratory Guide, L. A. King and R. D. Possee, Chapman and Hall, 1992) or pAc360 or pBlueBacHis (available from Invitrogen Corporation)).
- pAcYM1 see The Baculovirus Expression System: A Laboratory Guide, L. A. King and R. D. Possee, Chapman and Hall, 1992
- pAc360 or pBlueBacHis available from Invitrogen Corporation
- This recombinant construct was co-transfected into insect cells (for example Spodoptera frugiperda 21(Sf21)) with viral DNA (eg Pharmingen BaculoGold) to prepare recombinant baculovirus.
- insect cells for example Spodoptera frugiperda 21(Sf21)
- viral DNA eg Pharmingen BaculoGold
- cytoplasmic fragments starting from methionine 806 (KDR, Genbank accession number L04947) and methionine 668 (EGF receptor, Genbank accession number X00588) may be cloned and expressed in a similar manner.
- cFlt tyrosine kinase activity Sf21 cells were infected with plaque-pure cFlt recombinant virus at a multiplicity of infection of 3 and harvested 48 hours later.
- Harvested cells were washed with ice cold phosphate buffered saline solution (PBS) (10 mM sodium phosphate pH7A, 138 mM sodium chloride, 2.7 mM potassium chloride) then resuspended in ice cold HNTG/PMSF (20 mM Hepes pH7.5, 150 mM sodium chloride, 10% v/v glycerol, 1% v/v Triton X100, 1.5 mM magnesium chloride, 1 mM ethylene glycol-bis( ⁇ aminoethyl ether) N,N,N′,N′tetraacetic acid (EGTA), 1 mM PMSF (phenylmethylsulphonyl fluoride); the PMSF is added just before use from a
- a stock of substrate solution was prepared from a random copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at ⁇ 20° C. and diluted 1 in 500 with PBS for plate coating.
- a random copolymer containing tyrosine for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899)
- Test compounds were diluted with 10% dimethylsulphoxide (DMSO) and 25 ⁇ l of diluted compound was transferred to wells in the washed assay plates. “Total” control wells contained 10% DMSO instead of compound. Twenty five microlitres of 40 mM manganese(II)chloride containing 8 ⁇ M adenosine-5′-triphosphate (ATP) was added to all test wells except “blank” control wells which contained manganese(II)chloride without ATP. To start the reactions 50 ⁇ l of freshly diluted enzyme was added to each well and the plates were incubated at room temperature for 20 minutes. The liquid was then discarded and the wells were washed twice with PBST.
- DMSO dimethylsulphoxide
- mice IgG anti-phosphotyrosine antibody Upstate Biotechnology Inc. product 05-321
- PBST bovine serum albumin
- HRP horse radish peroxidase
- SSA bovine serum albumin
- ABTS 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
- This assay determines the ability of a test compound to inhibit the growth factor-stimulated proliferation of human umbilical vein endothelial cells (HUVEC).
- HUVEC human umbilical vein endothelial cells
- HUVEC cells were isolated in MCDB 131 (Gibco BRL)+7.5% v/v foetal calf serum (FCS) and were plated out (at passage 2 to 8), in MCDB 131+2% v/v FCS+3 ⁇ g/ml heparin+1 ⁇ g/ml hydrocortisone, at a concentration of 1000 cells/well in 96 well plates. After a minimum of 4 hours they were dosed with the appropriate growth factor (i.e. VEGF 3 ng/ml, EGF 3 ng/ml or b-FGF 0.3 ng/ml) and compound. The cultures were then incubated for 4 days at 37° C. with 7.5% carbon dioxide.
- FCS foetal calf serum
- This test measures the capacity of compounds to reduce the acute increase in uterine weight in rats which occurs in the first 4-6 hours following oestrogen stimulation.
- This early increase in uterine weight has long been known to be due to oedema caused by increased permeability of the uterine vasculature and recently Cullinan-Bove and Koos (Endocrinology, 1993,133:829-837) demonstrated a close temporal relationship with increased expression of VEGF mRNA in the uterus.
- prior treatment of the rats with a neutralising monoclonal antibody to VEGF significantly reduces the acute increase in uterine weight, confirming that the increase in weight is substantially mediated by VEGF.
- oestradiol benzoate Groups of 20 to 22-day old rats were treated with a single subcutaneous dose of oestradiol benzoate (2.5 ⁇ g/rat) in a solvent, or solvent only. The latter served as unstimulated controls. Test compounds were orally administered at various times prior to the administration of oestradiol benzoate. Five hours after the administration of oestradiol benzoate the rats were humanely sacrificed and their uteri were dissected, blotted and weighed. The increase in uterine weight in groups treated with test compound and oestradiol benzoate and with oestradiol benzoate alone was compared using a Student T test. Inhibition of the effect of oestradiol benzoate was considered significant when p ⁇ 0.05.
- a pharmaceutical composition which comprises a compound of the formula I as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.
- the composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream or for rectal administration for example as a suppository.
- parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
- a sterile solution, suspension or emulsion for topical administration for example as an ointment or cream or for rectal administration for example as a suppository.
- topical administration for example as an ointment or cream
- rectal administration for example as a suppository.
- the above compositions may be prepared in a conventional manner using conventional excipients.
- compositions of the present invention are advantageously presented in unit dosage form.
- the compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square metre body area of the animal, i.e. approximately 0.1-100 mg/kg.
- a unit dose in the range for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged and this normally provides a therapeutically-effective dose.
- a unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
- a compound of the formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
- compounds of the present invention inhibit VEGF receptor tyrosine kinase activity and are therefore of interest for their antiangiogenic effects and/or their ability to cause a reduction in vascular permeability.
- a further feature of the present invention is a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament, conveniently a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.
- a method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore.
- the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
- a daily dose in the range of 1-50 mg/kg is employed.
- the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- the antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
- the other component(s) of such conjoint treatment in addition to the antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy.
- Such chemotherapy may cover three main categories of therapeutic agent:
- the compounds defined in the present invention are of interest for their antiangiogenic and/or vascular permeability reducing effects.
- Such compounds of the invention are expected to be useful in a wide range of disease states including cancer, diabetes, psoriasis, rheumatoid artritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation.
- diseases of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin.
- Such compounds of the invention are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with VEGF especially those tumours which are significantly dependent on VEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.
- the compounds of formula I and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of VEGF receptor tyrosine kinase activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- Potassium carbonate (2.2 g, 16 mmol) was added to a solution of 4-3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline (1.51 g, 4 mmol) in DMF (30 ml) and the mixture stirred for 15 minutes.
- 2-Bromoethyl methyl ether (667 mg, 4.8 mmol) was then added dropwise. The mixture was stirred for 1 hour at ambient temperature, then heated at 60° C. for 17 hours and finally allowed to cool. The insoluble material was removed by filtration and the filter pad washed with DMF.
- the starting material was prepared as follows:
- Acetic anhydride (1.9 ml, 20.3 mmol) was added to a mixture of 2-methyl-5-nitrophenol (2.5 g, 16.3 mmol) and 1M aqueous sodium hydroxide (24.5 ml) at ambient temperature. The mixture was stirred for 40 minutes, the solid was removed by filtration and the filtrate extracted with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium chloride solution, dried (MgSO 4 ) and evaporated to yield 2-acetoxy-4-nitrotoluene (3.1 g, 100%).
- the starting material was prepared as follows:
- 1-2-Chloroethyl)pyrrolidine hydrochloride 200 mg, 1.2 mmol was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (403 mg, 1.26 mmol), (prepared as described for the starting material in Example 2), and potassium carbonate (650 mg, 4.7 mmol) in DMF (4 ml). The mixture was heated to 100° C. and further portions of 1-(2-chloroethyl)pyrrolidine hydrochloride (800 mg in total) were added periodically over 4 hours while the reaction mixture was maintained at 100° C. The reaction was then allowed to cool and volatiles were removed by evaporation.
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the purified product was recrystallised from methylene chloride/isohexane to give 4-chloro-2-fluoroanilino)-7-(2-methoxyethoxy)-6-nitroquinazoline (304 mg, 60%) as a yellow solid.
- the starting material was prepared as follows:
- Triphenylphosphine (410 mg, 1.5 mmol) and 1-methyl-3-pyrrolidinol (0.128 ml, 1.5 mmol) were added to a solution of 4-(chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250 mg, 0.78 mmol), (prepared as described for the starting material in Example 2), in methylene chloride (4 ml). Diethyl azodicarboxylate (0.246 ml, 1.5 mmol) was added dropwise and the reaction mixture was stirred for 1 hour at ambient temperature.
- Tetrakis(triphenylphosphine)palladium(0) 23 mg, 0.02 mmol
- a solution of sodium triisopropylsilylthiolate 102 mg, 0.48 mmol
- THF 2 ml
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(trifluoromethylsulphonyloxy)quinazoline 180 mg, 0.4 mmol
- the starting material was prepared as follows:
- Trifluoromethanesulphonic anhydride (0.55 ml, 3.3 mmol) was added to a stirred suspension of 4-(chloro-2-fluoroanilino)-7-hydroxy-6methoxyquinazoline (959 mg, 3 mmol), (prepared as described for the starting material in Example 2), in methylene chloride (2.2 ml) and pyridine (2.2 ml) under argon at 0° C.
- the reaction mixture was stirred for 1 hour at 0° C., allowed to warm to ambient temperature and stirred for a further 1.5 hours.
- the starting material was prepared as follows:
- the final compounds in Examples 13 and 14 may be mixed, in any relative proportions, for example to give a racemic mixture.
- racemate may be made as follows:
- 1,1′-(Azodicarbonyl)dipiperidine (560 mg, 2.2 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (240 mg, 0.75 mmol), (prepared as described for the starting material in Example 2), 1-methyl-3-piperidinemethanol (115 mg, 0.89 mmol) and tributylphosphine (440 mg, 2.2 mmol) in methylene chloride (10 ml). The mixture was stirred for 18 hours, diluted with ether and the resulting precipitate was removed by filtration.
- the solvent was removed from the filtrate by evaporation and the residue was purified by column chromatography eluting with methylene chloride/methanol (a gradient from 100/0 to 90/10).
- the semi-purified product was triturated with acetone and the solid product collected by filtration and dried to give further crude product (0.53 g).
- the filtrate from the trituration was repurified by column chromatography as before to give freer crude product (0.23 g).
- the crude products were combined and dissolved in acetone/methanol/methylene chloride and ethereal hydrogen chloride (6 ml of a 1M solution) added.
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- Example 25 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-methylthiopropoxy)quinazoline (250 mg, 0.6 mmol), (prepared as described in Example 21), was treated with OXONE, (trade mark of E.I. du Pont de Nemours & Co., Inc), (84 mg) and the product was pas and isolated to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-methylsulphinylpropoxy)quinazoline (75 mg, 29%).
- OXONE trade mark of E.I. du Pont de Nemours & Co., Inc
- the starting material was prepared as follows:
- 1,1′-(Azodicarbony)dipiperidine (1.56 g, 6.2 mmol) followed by 3-(methylthio)-1-propanol (0.32 ml, 3 mmol) was added to a mixture of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (225 mg, 7.0 mmol), (prepared as described for the starting material in Example 48), and tributylphosphine (1.42 mL 6.1 mmol) in methylene chloride (20 ml) at 5° C. The mixture was stirred at 5° C. for 1 hour and then for 18 hours at ambient temperature.
- 1,1′-(Azodicarbonyl)dipiperidine (355 mg, 1.4 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (150 mg, 0.47 mmol), (prepared as described for the starting material in Example 2), 2-(cyclopentyloxy)ethanol (91 mg, 0.7 mmol), (U.S. Pat. No. 4,515,814), and tributylphosphine (284 mg, 1.4 mmol) in methylene chloride (6 ml) at 0° C. The mixture was then allowed to warm to ambient temperature and stirred for 3.5 hours.
- reaction mixture was diluted with methylene chloride, washed with aqueous sodium hydrogen carbonate solution, water and then brine, dried (MgSO 4 ) and the solvent removed by evaporation.
- the residue was purified by column chromatography eluting with methylene chloride/methanol/aqueous ammonia (100/8/1).
- the product was recystallised from acetonitrile, collected by filtration, washed with ethyl acetate and dried to give 7-(2-[N-tert-butoxycarbonylamino]ethoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (235 mg, 25%).
- the starting material was prepared as follows:
- Triphenylphosphine (2.46 g, 9.3 mmol) was added to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (1.0 g, 3.1 mmol), (prepared as described for the starting material in Example 2), in methylene chloride (25 ml) and the suspension stirred at 0° C. for 30 minutes.
- a solution of 3-(N-tert-butoxycarbonylamino)-1-propanol (0.65 g, 3.7 mmol) in methylene chloride (3 ml) was added and then diethyl azodicarboxylate (1.47 ml, 7.6 mmol) was added dropwise.
- reaction mixture was allowed to warm to ambient temperature and stirred for 18 hours.
- the reaction mixture was diluted with methylene chloride and washed with aqueous sodium hydrogen carbonate solution, water and then brine.
- the resultant solution was dried (MgSO 4 ) and the solvent removed by evaporation.
- the residue was purified by column chromatography eluting with methylene chloride/methanol/triethylamine (100/0/0 and then 95/4/1) to give 7-(3-(N-tert-butoxycarbonylamino)propoxy)-4-(4-chloro-2-fluororanilino)-6-methoxyquinazoline (620 mg, 42%).
- 1,1′-(Azodicarbonyl)dipiperidine (560 mg, 2.2 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (240 mg, 0.75 mmol), (prepared as described for the starting material in Example 2), tetrahydro-3-furanmethanol (90 mg, 0.88 mmol) and tributylphosphine (440 mg, 2.2 mmol) in methylene chloride (12 ml) and the mixture stirred for 18 hours. The mixture was diluted with ether, and the resulting precipitate was removed by filtration.
- 1,1′-(Azodicarbonyl)dipiperidine (5.6 g, 22 mmol) was added in portions to a mixture of 4-(4chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (2.4 g, 7.5 mmol), (prepared as described for the starting material in Example 2), tributylphosphine (4.4 g, 22 mmol) and 1-(2-hydroxyethyl)-2-pyrrolidinone (1.1 g, 8.5 mmol) in methylene chloride (105 ml). The mixture was stirred for 18 hours, diluted with ether (100 ml) and the resulting precipitate was removed by filtration.
- 1,1′-(Azodicarbonyl)dipiperidine (525 mg, 2.1 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluroanilino)-7-hydroxy-6-methoxyquinazoline (225 mg, 7.0 mmol), (prepared as described for the starting material in Example 2), tributylphosphine (420 mg, 2.1 mmol) and 1-(2-hydroxyethyl)-2-imidazolidinone (100 mg, 7.7 mmol) in methylene chloride (10 ml). The mixture was stirred for 18 hours, diluted with ether and the resulting precipitate was removed by filtration.
- 1,1′-(Azodicarbonyl)dipiperidine (525 mg, 2.1 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (225 mg, 7.0 mmol), (prepared as described for the starting material in Example 2), tributylphosphine (420 mg, 2.1 mmol) and 4-(2-hydroxyethyl)-1,1-dioxothiomorpholine (140 mg, 7.8 mmol) in methylene chloride (10 ml). The mixture was stirred for 18 hours, diluted with ether and the resulting precipitate was removed by filtration.
- the starting material was prepared as follows:
- Ethyl 4chlorobutyrate (0.154 ml, 1.1 mmol) was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (319.5 mg, 1 mmol), (prepared as described for the starting material in Example 2), and anhydrous potassium carbonate (690 mg, 5 mmol) in DMF (10 ml). The mixture was stirred and heated at 105° C. for 4 hours then allowed to cool. The mixture was diluted with methylene chloride and the insolubles were removed by filtration.
- Oxalyl chloride (0.4 ml, 2.2 mmol) was added to a suspension of 7-(3-carboxypropoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (260 mg, 0.64 mmol), (prepared as described for the starting material in Example 42), in methylene chloride (25 ml) followed by 1 drop of DMF. The mixture was stirred at ambient temperature for 2.5 hours and the volatiles were removed by evaporation. A solution of pyrrolidine (0.13 ml, 2.1 mmol) in N,N-dimethylacetamide (8 ml) was added to the solid residue and the mixture was stirred at ambient temperature for 2 hours.
- the starting material was prepared as follows:
- Bromoacetaldehyde dimethyl acetal (0.74 ml, 3.1 mmol) was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (10 g, 3.13 mmol), (prepared as described for the starting material in Example 2), and anhydrous potassium carbonate (2.16 g, 15.6 mmol) in DMF (30 ml). The mixture was stirred and heated at 110° C. for 4 hours, then allowed t6 cool and the volatiles were removed by evaporation. Water was added to the residue and the aqueous mixture was extracted with methylene chloride ( ⁇ 4).
- Diethyl azodicarboxylate (261 mg, 1.5 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 2), triphenylphosphine (393 mg, 1.5 mmol) and 1-(3-hydroxypropyl)-2-pyrrolidinone (107 mg, 0.75 mmol) in methylene chloride (5 ml) under nitrogen.
- the mixture was stirred for 20 minutes at ambient temperature and then purified by pouring directly onto a column of silica eluting with methylene chloride/ethyl acetate/methanol (60/35/5 followed by 60/30/10).
- the purified product was triturated with ether and collected by filtration.
- the solid was dissolved in ethyl acetate and treated with 3M hydrogen chloride in ethyl acetate (0.4 ml).
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- Methanesulphonyl chloride 32 mg, 0.275 mmol was added dropwise to a mixture of 4-4-bromo-2-fluoroanilino)-6-methoxy-7-(3-metlylaminopropoxy)quinazoline (109 mg, 0.25 mmol) and triethylamine (30 mg, 0.3 mmol) in methylene chloride (3 ml) cooled at 0° C. The solution was stirred for 2 hours at 0° C. and the volatiles were removed by evaporation. The residue was partitioned between ethyl acetate and water, the organic layer was separated, washed with brine, dried (MgSO 4 and the solvent removed by evaporation.
- the solid was triturated with ether and collected by filtration.
- the solid was dissolved in methylene chloride containing methanol (0.5 ml) and 3M hydrogen chloride in ethyl acetate (0.3 ml) was added.
- the suspension was diluted with ethyl acetate and concentrated by evaporation.
- the resulting solid product was collected by filtration,-washed with ether and dried under vacuum to give 4-(4-bromo-2-fluoroanilino)-6-methoxy-(3([N-methyl-N-methylsulphonyl]amino)propoxy)quinazoline hydrochloride (85 mg, 61%).
- the starting material was prepared as follows:
- Diethyl azodicarboxylate (522 mg, 3 mmol) was added dropwise to a suspension of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (364 mg, 1 mmol), (prepared as described for the starting material in Example 48), triphenylphosphine (786 mg, 3 mmol) and 3-methylamino-1-propanol (178 mg, 2 mmol), (J.Am.Chem.Soc., 1954, 76, 2789), in methylene chloride (4 ml) under nitrogen. The mixture was stirred for 1 hour at ambient temperature, neutral alumina ( ⁇ 20 g) was added to the reaction mixture and the solvent was removed by evaporation.
- the powder was poured onto a column of neutral alumina and was eluted with a mixture of methylene chloride/methanol (95/5 followed by 90/10 and 80/20).
- the purified product was triturated with ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-methylaminopropoxy)quinazoline (220 mg, 50%).
- the mixture was then stirred for 2 hours at ambient temperature and the mixture was purified by pouring directly onto a column of silica and eluting with methylene chloride/ethyl acetate/methanol (60/35/5).
- the purified product was triturated with ether, collected by filtration, washed with ether and dried under vacuum.
- the solid was dissolved in methylene chloride and 3M hydrogen chloride in ethyl acetate (0.4 ml) was added.
- the starting material was prepared as follows:
- Methoxyacetyl chloride 34 mg, 0.31 mmol was added to a solution of 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methylaminoethoxy)quinazoline (113 mg, 0.3 mmol), (prepared as described for the starting material in Example 60), and triethylamine (33 mg, 0.33 mmol) in methylene chloride (3 ml). The mixture was stirred for 18 hours at ambient temperature and was then partitioned between ethyl acetate and brine. The organic layer was separated, dried (MgSO 4 ) and the solvent removed by evaporation.
- the residue was purified by chromatography on silica eluting with methylene chloride/acetonitrile/methanol (6/3/1).
- the purified solid product was triturated with methylene chloride and ether, collected by filtration, washed with ether and dried under vacuum.
- the solid was dissolved in a mixture of methylene chloride/methanol (1/1) and 2M hydrogen chloride in ethyl acetate (0.5 ml) was added.
- Diethyl azodicarboxylate (400 mg, 2.3 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250 mg, 0.78 mmol), (prepared as described for the starting material in Example 2), triphenylphosphine (615 mg, 2.3 mmol) and 4-(2-hydroxyethyl)-3-morpholinone (170 mg, 1.17 mmol), (EP 580402A2), in methylene chloride (5 ml) under nitrogen. The mixture was stirred for 4 hours at ambient temperature, methylene chloride (5 ml) was added and stirring was continued for a further 18 hours at ambient temperature. THF (5 ml).
- Diethyl azodicarboxylate (209 mg, 1.2 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6 methoxyquinazoline (128 mg, 0.4 mmol), (prepared as described for the starting material in Example 2), triphenylphosphine (314 mg, 1.2 mmol) and 2-(2-morpholinoethoxy)ethanol (97 mg, 0.56 mmol) in methylene chloride (4 ml) under nitrogen.
- the starting material was prepared as follows:
- 2-(2-Chloroethoxy)ethanol (1.25 g, 10 mmol) was added to a mixture of morpholine (2.58 g, 30 mmol) and potassium carbonate (5.5 g, 40 mmol) in acetonitrile (50 ml). The mixture was heated at reflux for 6 hours and then stirred for 18 hours at ambient temperature. The insolubles were removed by filtration and the volatiles were removed from the filtrate by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5 followed by 90/10 and then 80/20) to give 2-(2-morpholinoethoxy)ethanol (600 mg, 34%).
- Diethyl azodicarboxylate (209 mg, 1.2 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-methoxyquinazoline (128 mg, 0.4 mmol), (prepared as described for the starting material in Example 2), triphenylphosphine (314 mg, 1.2 mmol) and (S)-1-(3-hydroxypropyl)-pyrrolidine-2-carboxamide (97 mg, 0.56 mmol), (prepared as described for the starting material in Example 50), in methylene chloride (4 ml).
- Diethyl azodicarboxylate (209 mg, 1 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (128 mg, 0.4 mmol), (prepared as described for the starting material in Example 2), cis-3-(2,6-dimethylmorpholino)-1-propanol (97 mg, 0.56 mmol) and triphenylphosphine (314 mg, 1.2 mmol) in methylene chloride (4 ml) under nitrogen. The mixture was stirred for 1 hour at ambient temperature and the solvent was removed by evaporation.
- the starting material was prepared as follows:
- Diethyl azodicarboxylate (218 mg, 1.25 mmol) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (159 mg, 0.5 mmol), (prepared as described for the starting material in Example 2), 4-hydroxy-1-methylpiperidine (115 mg, 1 mmol) and triphenylphosphine (328 mg, 1.25mmol) in methylene chloride (5 ml) cooled at 5° C. under nitrogen. The mixture was stirred for 1 hour at ambient temperature, the solvent was removed by evaporation and the residue was partitioned between 2M hydrochloric acid and ether.
- the aqueous layer was separated, adjusted to pH9 with aqueous sodium hydrogen carbonate solution and extracted with methylene chloride.
- the methylene chloride layer was washed with brine, dried (MgSO 4 ) and the solvent removed by evaporation.
- the residue was purified on neutral alumina eluting with methylene chloride/methanol (97/3).
- the purified product was triturated with ether, collected by filtration and dried to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidine-4-yloxy)quinazoline (180 mg, 79%).
- Methanesulphonyl chloride 35 ⁇ l, 0.46 mmol was added dropwise to a solution of 4-(4-chloro-2-fluoro)-6-methoxy-7-(3-methyl aminopropoxy)quinazoline (170 mg, 043 mmol) and triethylamine (67 ⁇ l, 0.48 mmol) in methylene chloride (3 ml). The mixture was stirred for 5 hours at ambient temperature, the volatiles was removed by evaporation and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and then brine, dried (MgSO 4 ) and the solvent removed by evaporation.
- the staring material was prepared as follows:
- Diethyl azodicarboxylate (2.4 ml, 15 mmol) was added dropwise to a solution of 3-([N-(tert-butylcarbonyl)-N-methyl]amino)-1-propanol (1.77 g, 9.4 mmol), 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (2 g, 6.26 mmol), (prepared as described for the starting material in Example 2), and triphenylphosphine (4.1 g, 15 mmol) in methylene chloride (50 ml) under nitrogen.
- the purified product was triturated with ether, collected by filtration and repurified by column chromatography eluting with methylene chloride/methanol (97/3) to give 7-3-([N-(tert-butylcarbonyl)-N-methyl]amino)propoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (2.2 g, 72%).
- the starting material was prepared as follows:
- Diethyl azodicarboxylate (3.13 g, 24 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (2.56 mg, 8 mmol), (prepared as described for the starting material in Example 2), 2-[(N-(tert-butylcarbonyl)-N-methyl]amino)ethanol (2.1 g, 1.2 mmol), (Synth. Commun. 1993, 23, 2443), and triphenylphosphine (63 g, 24 mmol) in methylene chloride (50 ml) under nitrogen.
- the starting material was prepared as follows:
- 1,2-Dibromoethane (5.4 ml, 62 mmol) was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (5 g, 15.6 mmol), (prepared as described for the starting material in Example 2), and potassium carbonate (8.6 g, 62 mmol) in DMF (50 ml) and the mixture stirred for 18 hours at ambient temperature. Water was added and the resulting precipitate was collected by filtration. The solid was purified by chromatography on neutral alumina eluting with methylene chloride/methanol (95/5).
- the semi-purified product was repurified by chromatography on silica eluting with methylene chloride/methanol (97/3).
- the purified product was triturated with ether, collected by filtration, washed with ether and dried under vacuum to give 7-(2-bromoethoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (3.58 g, 54%).
- the starting material was prepared as follows:
- 2-Bromoethyl ether (1.57 ml, 12 mmol) was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (1 g, 3.1 mmol), (prepared as described for the starting material in Example 2), and potassium carbonate (1.73 g, 12 mmol) in DMF (10 ml).
- the mixture was s for 18 hours at ambient temperature and was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and then brine, dried (MgSO 4 ) and the solvent removed by evaporation.
- the residue was purified by column chromatography on alumina eluting with methylene chloride/acetonitrile/methanol (60/37/3).
- the semi-purified product was repurified by column chromatography on silica eluting with methylene chloride/methanol (95/5).
- the purified product was dissolved in methylene chloride and 2.9M ethereal hydrogen chloride (1 ml) was added.
- the starting material was prepared as follows:
- Diethyl azodicarboxylate (368 ⁇ l, 2.34 mmol) was added dropwise to a mixture of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (284 mg, 0.78 mmol), (prepared as described for the starting material in Example 48), triphenylphosphine (613 mg, 2.34 mmol) and 4-(2-hydroxyethyl)-3-morpholinone (170 mg, 1.17 mmol), (EP580402A2), in methylene chloride (10 ml) under nitrogen. The mixture was stirred for 2.5 hours at ambient temperature, the insolubles were removed by filtration.
- the filtrate was purified by pouring it directly on to a column of silica and eluting with methylene chloride/ethyl acetate/methanol (60/35/5).
- the purified product was triturated with ether and collected by filtration.
- the solid was dissolved in methylene chloride containing a few drops of methanol and 3.8M ethereal hydrogen chloride (0.5 ml) was added.
- Diethyl azodicarboxylate (283 ⁇ l, 1.8 mmol) was added dropwise to a mixture of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (218 mg, 0.6 mmol), (prepared as described for the starting material in Example 48), triphenylphosphine (95 ⁇ l, 0.84 mmol) and 1-(2-hydroxyethyl)-2-pyrrolidinone (95 ⁇ l, 0.84 mmol) in methylene chloride (8 ml) under nitrogen.
- the mixture was stirred for 4 hours at ambient temperature, and then purified by pouring it directly on to a column of silica and eluting with methylene chloride/acetonitrile/methanol (60/32.5/7.5).
- the purified product was triturated with ether and collected by filtration.
- the solid was dissolved in methylene chloride/methanol (1/1) and 2M ethereal hydrogen chloride (1 ml) was added.
- Diethyl azodicarboxylate (236 ⁇ l, 1.5 mmol) was added dropwise to a mixture of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (182 mg, 0.5 mmol), (prepared as described for the starting material in Example 48), triphenylphosphine (393 mg, 1.5 mmol) and 2-(2-methoxyethoxy)ethanol (84 ⁇ l, 0.7 mmol) in methylene chloride (7 ml) under nitrogen.
- the mixture was stirred for 4 hours at ambient temperature, the reaction mixture was purified by pouring it directly on to a column of silica and eluting with ethyl acetate/petroleum ether (9/1 followed by 10/0). The purified product was triturated with ether and collected by filtration. The solid was dissolved in methylene chloride/methanol and 2M ethereal hydrogen chloride (1 ml) was added.
- Diethyl azodicarboxylate (567 ⁇ l, 3.6 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (383 mg, 1.2 mmol), (prepared as described for the starting material in Example 2), 4-(3-hydroxypropyl)-3,5-dioxomorpholine (291 mg, 1.68 mmol) and triphenylphosphine (944 mg, 3.6 mmol) in methylene chloride (10 ml) under nitrogen. The mixture was sired at ambient temperature for 6 hours and the insolubles were removed by filtration.
- the filtrate was purified by pouring it directly on to a column of silica and eluting with methylene chloride/acetonitrile/methanol (60/34/6 followed by 60/24/16 and 60/16/24).
- the semi-purified product was repurified by column chromatography eluting with methylene chloride/acetonitrile/methanol (5/4/1).
- the purified product was dissolved in methylene chloride/methanol 2M ethereal hydrogen chloride (1 ml) was added and the volatiles were removed by evaporation.
- the starting material was prepared as follows:
- Diethyl azodicarboxylate (472 ⁇ l, 3 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (319.5 mg, 1 mmol), (prepared as described for the staring material in Example 2), triphenylphosphine (786 mg, 3 mmol) and 4-(2-hydroxyethyl)-3,5-dioxomorpholine (223 mg, 1.4 mmol) in methylene chloride (10 ml) under nitrogen. The mixture was stirred at ambient temperature for 4.5 hours and the insolubles were removed by filtration.
- the starting material was prepared as follows:
- Ethanolamine (2.44 g, 40 mmol) was added dropwise to a solution of diglycolic anhydride (2.32 g, 20 mmol) in pyridine (10 ml). The mixture was stirred for 5 minutes at ambient temperature and then heated at reflux for 2 hours. The volatiles were removed by evaporation and the residue was heated at 180° C. for 2 hours The reaction mixture was allowed to cool and was purified by column chromatography eluting with methylene chloride/methanol (9/1) to give 4-(2-hydroxyethyl)-3,5-dioxomorpholine (400 mg, 12.5%).
- Diethyl azodicarboxylate (378 ⁇ l, 2.4 mmol) was added dropwise to a mixture of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (292 mg, 0.8 mmol), (prepared as described for the starting material in Example 48), triphenylphosphine (629 mg, 2.4 mmol) and 2-(2-morpholinoethoxy)ethanol (196 mg, 1.12 mmol), (prepared as described for the starting material in Example 53), in methylene chloride (10 ml) under nitrogen.
- the mixture was stirred for 3.5 hours at ambient temperature and the mixture was purified by pouring it directly on to a column of silica and eluting with methylene chloride/acetonitrile/methanol 6/3/1).
- the purified product was dissolved in methylene chloride/methanol and the insolubles were removed by filtration. 2M Ethereal hydrogen chloride (1 ml) was added to the filtrate and the volatiles were removed by evaporation.
- Diethyl azodicarboxylate (220 ⁇ l, 1.4 mmol) was added dropwise to a mixture of 4-(4-bromo-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (170 mg, 0.46 mmol), (prepared as described for the starting material in Example 48), triphenylphosphine (367 mg, 1.4 mmol) and 3-(1,1-dioxothiomorpholino)-1-propanol (135 mg, 0.7 mmol) in methylene chloride (4 ml) under nitrogen.
- the starting material was prepared as follows:
- the mixture was stirred for 10 minutes at ambient temperature, the volatiles were removed by evaporation and the residue was partitioned between methylene chloride and water. The organic layer was separated, washed with brine, dried (MgSO 4 ) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (97/3). The purified product was dissolved in methylene chloride (5 ml) and 2.2M ethereal hydrogen chloride (2 ml) was added and the volatiles were removed by evaporation.
- Example 74 Using a method analogous to that in Example 74, a mixture of 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-methylaminoethoxy)quinazoline (102 mg, 0.27 mmol), (prepared as described for the staring material in Example 60), and triethylamine (0.1 ml, 0.72 mmol) in acetonitrile (17 ml) was treated with 3-morpholinopropylsulphonyl chloride (75 mg, 0.28 mmol), (WO 930181), to give, after purification and hydrochloride salt formation, 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-([N-methyl-N-(3-morpholinopropylsulphonyl)]amino)ethoxy)quinazoline hydrochloride (96 mg, 54%).
- Diethyl azodicarboxylate (0.18 ml, 1.14 mmol) was added dropwise to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (111 mg, 0.35 mmol), (prepared as described for the staring material in Example 2), triphenylphosphine (312 mg, 1.19 mmol) and (S)-1-(3-hydroxypropyl)-2-(N,N-dimethylcarbamoyl)pyrrolidine (84 mg, 0.42 mmol) in methylene chloride (10 ml) cooled at 0° C. under nitrogen.
- the aqueous layer was separated, adjusted to pH9 with sodium hydrogen carbonate and was extracted with methylene chloride.
- the combined organic extracts were washed with water and then brine, dried (MgSO 4 ) and the solvent removed by evaporation.
- the residue was purified by column chromatography on silica eluting with methylene chloride/methanol (85/15 followed by 75/25 and 60/40).
- the purified product was dissolved in methylene chloride (5 ml) and methanol (1 ml), 3.9M ethereal hydrogen chloride (0.5 ml) was added and the mixture was diluted with ether.
- the starting material was prepared as follows:
Abstract
wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected from alkyl and a 5 or 6 membered saturated carbocyclic or heterocyclic group, and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
Description
-
- m is an integer from 1 to 2;
- R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl);
- R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro;
- R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyolxy, trifluoromethyl, cyano, amino or nitro;
- X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl);
- R4 is selected from one of the following eight groups:
- 1) C1-5alkylR12 (wherein R12 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C1-5alkyl through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl) or C1-5alkylR13 (wherein R13 is a group selected from pyrrolidin-1-yl, imidazolidin-1-yl and thiomorpholino, which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 2) C2-5alkenylR14 (wherein R14 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 3) C2-5alkynylR15 (wherein R15 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 4) C1-5alkylX2C1-5alkylX3R16 (wherein X2 and X3 which may be the same or different are each —O—, —S—, —SO—, —SO2—, —NR17CO—, —CONR18—, —SO2NR19—, —NR20SO2— or —NR21— (wherein R17, R18, R19, R20 and R21 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R16 represents hydrogen or C1-3alkyl) with the proviso that X1 cannot be —C2— when R4 is C1-5alkylX2C1-5alkylX3R16;
- 5) C1-5alkylX4COR22 (wherein X4 represents —O— or —NR23— (wherein R23 represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R22 represents —NR24R25 or —OR 26 (wherein R24, R25 and R26 which may be the same or different each represents hydrogen, C1-4alkyl or C1-3alkoxyC2-3alkyl));
- 6) C1-5alkylX5R27 (wherein X5 represents —O—, —S—, —SO—, —SO2—, —OCO—, —NR28CO—, —CONR29—, —SO2NR30—, —NR31SO2— or —NR32— (wherein R28, R29, R30, R31 and R32 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) or X5 is carbonyl, and R27 represents cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which cyclopentyl, cyclohexyl or heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl or R27 is C1-3alkyl with the proviso that when R27 is C1-3alkyl, X5 is —S—, —SO—, —SO2—, —SO2NR30— or —NR31SO2— and X1 is not —CH2—);
- 7) C1-3alkoxyC2-4alkyl provided that X1 is —S—, or X1 is —SO— or —SO2—; and
- 8) C1-3alkoxyC2-4alkyl or C1-4alkyl provided that X1 is —O—; and additionally R4 may be selected from the following five groups:
- 9) C1-5alkylX6C1-5alkylR33 (wherein X6 represents —O—, —S—, —SO—, —SO2—, —NR34CO—, —CONR35—, —SO2NR36—, —NR37SO2— or —NR38— (wherein R34, R35, R36, R37 and R38 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 represents cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which cyclopentyl, cyclohexyl or heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl, C1-4alkoxy, carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 10) R39 (wherein R39 is a group selected from pyrrolidin-3-yl, piperidin-3-yl and piperidin-4-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl, C1-4alkoxy, carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 11) C1-5alkylR40 (wherein R40 is piperazin-1-yl which bears at least one substituent selected from C1-4alkanoyl, C1-4alkoxycarbonyl, C1-4hydroxyalkyl and —CONR41R42 (wherein R41 and R42 each independently represents hydrogen or C1-4alkyl);
- 12) C1-5alkylR43 (wherein R43 is morpholino which may bear one or two substituents selected from oxo, C1-4alkyl, C1-4hydroxyalkyl, carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl) with the proviso that when R4 is C1-5alkylR43, X1 is —S—, —SO—, —SO2—, —SO2NR9— or —NR10SO2—; and
- 13) C1-5alkylR44 (wherein R44 is morpholino which bears at least one and optionally two substituents selected from oxo, C1-4alkyl, C1-4hydroxyalkyl, carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl); with the further proviso that when R4 is selected from group 8) R1 and/or R2 is/are nitro or at least one R3 is C1-3alkanoyloxy;]
and salts thereof.
-
- Ra represents hydrogen, methyl, fluoro or chloro, preferably hydrogen or fluoro;
- Rb represents hydrogen, methyl, methoxy, bromo, fluoro or chloro, especially hydrogen, methyl or chloro;
- Rc represents hydrogen or hydroxy;
- Rd represents hydrogen, fluoro or chloro, especially hydrogen or fluoro.
-
- 1) C1-5alkylR12 (wherein R12 is a group selected from 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl and pyrrolidin-3-yl, and piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl) or C2-5alkylR45 (wherein R45 is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino, which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 2) C3-5alkenylR46 (wherein R46 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C3-5alkenyl through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl) or C4-5alkenylR47 (wherein R47 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to C4-5alkenyl through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 3) C3-5alkynylR48 (wherein R48 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C3-5alkynyl through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl) or C4-5alkynylR49 (wherein R49 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to C4-5alkynyl through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 4) C2-3alkylX2C2-3alkylX3R16 (wherein X2 and X3 are as defined hereinbefore and R16 represents hydrogen or C1-3alkyl) with the proviso that X1 cannot be —CH2— when R4 is C2-3alkylX2C2-3alkylX3R16;
- 5) C2-3alkylX4COR22 (wherein X4 is as defined hereinbefore and R22 represents —NR24R25 or —OR26 (wherein R24, R25 and R26 which may be the same or different each represents hydrogen, C1-4alkyl or C1-2alkoxyethyl));
- 6) C2-4alkylX5R27 (wherein X5 is as defined hereinbefore and R27 represents cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which cyclopentyl, cyclohexyl or heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl or R27 is C1-3alkyl with the proviso that when R27 is C1-3alkyl, X5 is —S—, —SO—, —SO2—, —SO2NR30— or —NR31SO2— and X1 is not —CH2—);
- 7) C1-3alkoxyC2-4alkyl provided that X1 is —S—, or X1 is —SO— or —SO2—; and
- 8) C1-3alkoxyC2-4alkyl or C1-4alkyl provided that X1 is —O—; and additionally R4 may conveniently be selected from the following four groups:
- 9) C2-4alkylX6C2-4alkylR33 (wherein X6 is as defined hereinbefore and R33 represents a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl, C1-4alkoxy, carbamoyl, C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, C1-4alkanoyl and C1-4alkoxycarbonyl);
- 10) C2-4alkylyR40 (wherein R40 is piperazin-1-yl which bears at least one substituent selected from C2-3alkanoyl, C1-3alkoxycarbonyl, C1-3hydroxyalkyl and CONR41R42 (wherein R41 and R42 each independently represents hydrogen or C1-3alkyl));
- 11) C2-4alkylR43 (wherein R43 is morpholino which may bear one or two substituents selected from oxo, C1-3alkyl, C1-3hydroxyalkyl, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl) with the proviso that when R4 is C2-4alkyl R43, X1 is —S—, —SO—, —SO2—, —SO2NR9— or —NR10SO2—; and
- 12) C2-4alkylR44 (wherein R44 is morpholino which bears at least one and optionally two substituents selected from oxo, C1-3alkyl, C1-3hydroxyalkyl, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl);
- with the further proviso that when R4 is selected from group 8) R1 and/or R2 is/are nitro or at least one R3 is C1-3alkanoyloxy.
-
- 1) C1-4alkylR12 (wherein R12 is a group selected from 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl and pyrrolidin-3-yl, and piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl) or C2-4alkylR45(wherein R45 is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl);
- 2) 1-R46prop-1-en-3-yl, 1-R46but-2-en-4-yl, 1-R46but-1-en-3-yl, 1-R46pent-2-en-4-yl or 2-R46pent-3-en-5-yl (wherein R46 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamnoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl) or 1-R47but-2-en-4-yl, 1-R47pent-2-en-4-yl or 2-R47pent-3-en-5-yl (wherein R47 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl);
- 3) 1-R48prop-1-yn-3-yl, 1-R48but-2-yn-4-yl, 1-R48but-1-yn-3-yl, 1-R48pent-2-yn-4-yl or 2-R48pent-3-yn-5-yl (wherein R48 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl) or 1-R49but-2-yn-4-yl, 1-R49pent-2-yn-4-yl or 2-R49pent-3-yn-5-yl (wherein R49 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl);
- 4) C2-3alkylX2C2-3alkylX3R16 (wherein X2 and X3 are as defined hereinbefore and R16 represents hydrogen or C1-3alkyl) with the proviso that X1 cannot be —CH2— when R4 is C2-3alkylX2C2-3alkylX3R16;
- 5) C2-3alkylX4COR22 (wherein X4 is as defined hereinbefore and R22 represents —NR24R25 or —OR26 (wherein R24, R25 and R26 which may be the same or different each represents hydrogen, C1-4alkyl or C1-2alkoxyethyl));
- 6) C2-3alkylX5R27 (wherein X5 is as defined hereinbefore and R27 represents a group selected from cyclopentyl, cyclohexyl pyrrolidinyl and piperidinyl which group is linked to X5 through a carbon atom and which group may carry one substituent selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl and C1-2alkoxy, and additional possible substituents are carbamoyl, C1-2akylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl or R27 is C1-3alkyl with the proviso that when R27 is C1-3alkyl, X5 is —S—, —SO—, —SO2—, —SO2NR30— or —NR31SO2— and X1 is not —CH2—); and
- 7) C1-2alkoxyC2-3alkyl provided that X1 is —S—, or X1 is —SO— or —SO2—; and additionally R4 may advantageously be selected from the following four groups:
- 8) C2-3alkylX6C2-3alkylR33 (wherein X6 is as defined hereinbefore and R33 represents a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl, and C1-3alkoxycarbonyl);
- 9) C2-3alkylR40 (wherein R40 is piperazin-1-yl which bears at least one substituent selected from acetyl, C1-2alkoxycarbonyl, C1-2hydroxyalkyl and CONR41R42 (wherein R41 and R42 each independently represents hydrogen or C1-2alkyl);
- 10) C2-3alkylR43 (wherein R43 is morpholino which may bear one or two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl) with the proviso that when R4 is C2-3alkylR43, X1 is —S—, —SO—, —SO2—, —SO2NR9— or —NR10SO2—; and
- 11) C2-3alkylR44 (wherein R44 is morpholino which bears at least one and optionally two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl).
-
- 1) C1-3alkylR12 (wherein R12 is a group selected from 1,3dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl and pyrrolidin-3-yl and piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, acetyl and C1-3alkoxycarbonyl) or C2-3alkylR45 (wherein R45 is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, acetyl and C1-3alkoxycarbonyl);
- 2) 1-R46but-2-en-4-yl (wherein R46 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, acetyl and C1-3alkoxycarbonyl) or 1-R47but-2-en-4-yl (wherein R47 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, acetyl and C1-3alkoxycarbonyl);
- 3) 1-R48but-2-yn-4-yl (wherein R48 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, acetyl and C1-3alkoxycarbonyl) or 1-R49but-2-yn-4-yl (wherein R49 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl and C1-3alkoxy, and additional possible substituents are carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, acetyl and C1-3alkoxycarbonyl);
- 4) C2-3alkylX2C2-3alkylX3R16 (wherein X2 and X3 are as defined hereinbefore and R16 represents hydrogen or C1-3alkyl) with the proviso that X1 cannot be —CH2— when R4 is C2-3alkylX2C2-3alkylX3R16;
- 5) 2-(3,3-dimethylureido)ethyl, 3-(3,3-dimethylureido)propyl, 2-(3-methylureidoethyl)ethyl, 3-(3-methylureido)propyl, 2-ureidoethyl, 3-ureidopropyl, 2-(N,N-dimethylcarbamoyloxy)ethyl, 3-(N,N-dimethylcarbamoyloxy)propyl, 2-(N-methylcarbamoyloxy)ethyl, 3-(N-methylcarbamoyloxy)propyl, 2-(carbamoyloxy)ethyl, 3-(carbamoyloxy)propyl or 2-(1,3,3-trimethylureido)ethyl, 3-(1,3,3-trimethylureido)propyl, 2-(isopropoxycarbonylamino)ethyl, 3-(isopropoxycarbonylamino)propyl, 2-(isobutoxycarbonylamino)ethyl, 3-(isobutoxycarbonylamino)propyl, 2-(t-butoxycarbonylamino)ethyl or 3-(t-butoxycarbonylamino)propyl;
- 6) C2-3alkylX5R27 (wherein X5 is as defined hereinbefore and R27 is a group selected from cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X5 through a carbon atom and which group may carry one substituent selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl and C1-2alkoxy and additional possible substituents are carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl or R27 is C1-2alkyl with the proviso that when R27 is C1-2alkyl, X5 is —S—, —SO—, —SO2—, —SO2NR30— or —NR31SO2— and X1 is not —CH2—); and
- 7) C1-2alkoxyC2-3alkyl provided that X1 is —S—, or X1 is —SO— or —SO2—; and additionally R4 may preferably be selected from the following three groups:
- 8) C2-3alkylX6C2-3alkylR33 (wherein X6 is as defined hereinbefore and R33 represent a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, of which at least one is N, which heterocyclic group is linked to C2-3alkyl through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl, C1-2alkoxy, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl);
- 9) C2-3alkylR43 (wherein R43 is morpholino which may bear one or two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl) with the proviso that when R4 is C2-3alkylR43, X1 is —S—, —SO—, —SO2—, —SO2NR9— or —NR10SO2—); and
- 10) C2-3alkylR44 (wherein R44 is morpholino which bears at least one and optionally two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl).
-
- 1) C1-3alkylR12 (wherein R12 is a group selected from 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl and pyrrolidin-3-yl and piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl and C1-2alkoxy, and additional possible substituents are carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl) or C2-3alkylR45 (wherein R45 is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl and C1-2alkoxy, and additional possible substituents are carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl);
- 2) 1-R50but-2-en-4-yl (wherein R50 is a group selected from imidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3dithian-2-yl, piperidin-4-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperazin-1-y1, morpholino and thiomorpholino and piperidino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl and C1-2alkoxy, and additional possible substituents are carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl); 3) 1-R51but-2-yn-4-yl (wherein R51 is a group selected from imidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, piperidin-4-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, pipeiain-1-yl, morpholino and thiomorpholino and piperidino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl and C1-2alkoxy, and additional possible substituents are carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl);
- 4) C2-3alkylX2C2-3alkylX3R16 (wherein X2 and X3 are as defined hereinbefore and R16 represents hydrogen or C1-3alkyl) with the proviso that X1 cannot be —CH2— when R4 is C2-3alkylX2C2-3alkylX3R16; and
- 5) C2-3alkoxyC2-3alkyl provided that X1 is —S—, or X1 is —SO— or —SO2—; and additionally R4 may more preferably be selected from the following four groups:
- 6) 2-(3,3-dimethylureido)ethyl, 3-(3,3-dimethylureido)propyl, 2-(3-methylureido)ethyl, 3-(3-methylureido)propyl, 2-ureidoethyl, 3-ureidopropyl, 2-(N,N-dimethylcarbamoyloxy)ethyl, 3-(N,N-dimethylcarbamoyloxy)propyl, 2-(N-methylcarbamoyloxy)ethyl, 3-(N-methylcarbamoyloxy)propyl, 2-(carbamoyloxy)ethyl, 3-(carbamoyloxy)propyl, 2-(1,3,3-trimethylureido)ethyl, 3-(1,3,3-trimethylureido)propyl, 2-(isopropoxycarbonylamino)ethyl, 3-(isopropoxycarbonylamino)propyl, 2-(isobutoxycarbonylamino)ethyl, 3-(isobutoxycarbonylamino)propyl, 2-(t-butoxycarbonylamino)ethyl or 3-(t-butoxycarbonylamino)propyl;
- 7) C2-3alkylX5R27 (wherein R27 is C1-2alkyl and X5 is —S—, —SO—, —SO2—, —SO2NR30— or —NR31SO2— and with the proviso that X1 is not —CH2—);
- 8) C2-3alkylX6C2-3alkylR33 (wherein X6 is as defined hereinbefore and R33 represents a group selected from morpholino, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, piperidino, piperazin-1-yl and 4-methylpiperazin-1-yl); and
- 9) C2-3alkylR43 (wherein R43 is morpholino which may bear one or two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl) with the proviso that when R4 is C2-3alkylR43, X1 is —S—, —SO—, —SO2—, —SO2NR9— or —NR10SO2—.
-
- 1) C1-3alkylR12 (wherein R12 is 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2yl, 1,3-dithian-2-yl, pyrrolidin-2-yl or pyrrolidin-3-yl or piperidin-2-yl, piperidin-3-yl piperidin-4-yl, 1-methylpiperidin-2-yl, 1-methylpiperidin-3-yl, 1-methylpiperidin-4-yl, 1-methylpyrrolidin-2-yl, 1-methylpyrrolidin-3-yl, piperazin-2-yl, 1-methylpiperazin-2-yl, 4-methylpiperazin-2-yl, 1,4-dimethylpiperazin-2-yl, morpholin-2-yl, morpholin-3-yl, 4-methylmorpholin-2-yl or 4-methylmorpholin-3-yl) or C2-3alkylR45 (wherein R45 is pyrrolidin-1-yl or thiomorpholino or 1,1-dioxothiomorpholino, 2-oxopyrrolidin-1-yl, 2(N-methylcarbamoyl)pyrrolidin-1-yl, 2-(N,N-diethylcarbamoyl)pyrrolidin-1-yl, 2-carbamoylpyrrolidin-1-yl, 2-oxoimidazolidin-1-yl or 3-methyl-2-oxoimidazolidin-1-yl);
- 2) 1-R50but-2-en-4-yl (wherein R50 is 2-oxoimidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, pyrrolidin-1-yl, 1-methylpyrrolidin-3-yl, piperazin-1-yl, morpholino or thiomorpholino or 4-methylpiperazin-1-yl, piperidino or 3-methyl-2-oxoimidazolidin-1-yl);
- 3) 1-R51but-2-yn-4-yl (wherein R51 is 2-oxoimidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, pyrrolidin-1-yl, 1-methylpyrrolidin-3-yl, piperazin-1-yl, morpholino or thiomorpholino or 4-methylpiperazin-1-yl, piperidino or 3-methyl-2-oxoimidazolidin-1-yl);
- 4) C2-3alkylX2C2-3alkylX3R16 (wherein X2 and X3 are as defined hereinbefore and R16 represents hydrogen or C1-3alkyl) with the proviso that X1 cannot be —CH2— when R4 is C2-3alkylX2C2-3alkylX3R16; and
- 5) C1-2alkoxyC2-3alkyl provided that X1 is —S—, or X1 is —SO— or —SO2—; and additionally R4 may most preferably be selected from the following three groups:
- 6) C2-3alkylX5R27 (wherein R27 is C1-2alkyl and X5 is —S—, —SO—, —SO2—, —SO2NR30— or —NR31SO2— and with the proviso that X1 is not —CH2—);
- 7) C2-3alkylX6C2-3alkylR33 (wherein X6 is as defined hereinbefore and R33 represents a group selected from pyrrolidin-1-yl, 4-methylpiperazin-1-yl and morpholino); and
- 8) C2-3alkylR43 (wherein R43 is morpholino which may bear one or two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl) with the proviso that when R4 is C2-3alkylR43, X1 is —S—, —SO—, —SO2—, —SO2NR9— or —NR10SO2—.
-
- R1a is hydrogen or methoxy;
- R2a is hydrogen;
- the phenyl group bearing (R3a)ma is the 4-chloro-2-fluorophenyl group or the 4-bromo-2-fluorophenyl group;
- X1a is —O—, —S—, —NR5aCO— or —NR6aSO2— (wherein R5a and R6a each independently represents hydrogen or C1-2alkyl);
- R4a is selected from one of the following eleven groups:
- 1) C1-4alkylR7a (wherein R7a is a group selected from 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl and pyrrolidin-3-yl, and piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl) or C2-4alkylR8a (wherein R8a is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl);
- 2) 1-R9aprop-1-en-3-yl, 1-R9abut-2-en-4-yl, 1-R9abut-1-en-3-yl, 1-R9apent-2-en-4-yl or 2-R9apent-3-en-5-yl (wherein R9a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl) or 1-R10abut-2-en-4-yl, 1-R10apent-2-en-4-yl or 2-R10apent-3-en-5-yl (wherein R10a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which Eone is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl);
- 3) 1-R11aprop-1-yn-3-yl, 1-R11abut-2-yn-4-yl, 1-R11abut-1-yn-3-yl, 1-R11apent-2-yn-4-yl or 2-R11apent-3-yn-5-yl (wherein R11a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo; hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl) or 1-R12abut-2-yn-4-yl, 1-R12apent-2-yn-4-yl or 2-R12apent-3-yn-5-yl (wherein R12a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C2-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl and C1-3alkoxycarbonyl);
- 4) C2-3 alkylX2aC2-3alkylX3aR13a (wherein X2a and X3a which may be the same or different each represents —O—, —S—, —SO—, —SO2—, —NR14aCO—, or —NR15a— (wherein R14a and R15a each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl) and R13a represents hydrogen or C1-3alkyl);
- 5) C2-3alkylX4aCOR16a (wherein X4a represents —O— or —NR17a— (wherein R17a represents hydrogen C1-3alkyl or C1-2alkoxyethyl) and R16a represents —NR18aR19a or —OR20a (wherein R18a, R19a and R20a which may be the same or different each represents hydrogen, C1-4alkyl or C1-2alkoxyethyl));
- 6) C2-3alkylX5aR21a (wherein X5a represents carbonyl, —O—, —S—, —SO—, —SO2—, —NR22aCO—, —NR23aSO2— or —NR24a— (wherein R22a, R23a and R24a each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl) and R21a represents a group selected from cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X5a through a carbon atom and which group may carry one substituent selected from oxo, hydroxy, halogeno, C1-2alkyl, C1-2hydroxyalkyl, C1-2alkoxy, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl or R21a is C1-3alkyl with the proviso that when R21a is C1-3alkyl, X5a is —S—, —SO—, —SO2— or —NR23aSO2—); and
- 7) C1-2alkoxyC2-3alkyl provided that X1a is —S—;
- 8) C2-3alkylX6aC2-3alkylR25a (wherein X6a represents —O—, —S—, —SO2—, —SO—, —NR26aCO—, —NR27aSO2— or —NR28a— (wherein R26a, R27a and R28a each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl) and R25a represents a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C1-3alkyl, C1-3hydroxyalkyl, C1-3alkoxy, carbamoyl, C1-3alkylcarbamoyl, N,N-di(C1-3alkyl)carbamoyl, C2-3alkanoyl, and C1-3alkoxycarbonyl);
- 9) C2-3alkylR29a (wherein R29a is piperazin-1-yl which bears at least one substituent selected from acetyl, C1-2alkoxycarbonyl, C1-2hydroxyalkyl and CONR30aR31a (wherein R30a and R31a each independently represents hydrogen or C1-2alkyl);
- 10) C2-3alkylR32a (wherein R32a is morpholino which may bear one or two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)cabamoyl, acetyl and C1-2alkoxycarbonyl) with the proviso that when R4a is C2-3alkylR32a, X1a is —S— or —NR6aSO2— (wherein R6a is as defined hereinbefore); and
- 11) C2-3alkylR33a (wherein R33a is morpholino which bears at least one and optionally two substituents selected from oxo, C1-2alkyl, C1-2hydroxyalkyl, carbamoyl, C1-2alkylcarbamoyl, N,N-di(C1-2alkyl)carbamoyl, acetyl and C1-2alkoxycarbonyl); and an additional value of R4a is C2-3alklyX2amethylX3aR13a (wherein X2a and X3a are as defined hereinbefore and R13a represents hydrogen or C1-3alkyl);] and salts thereof.
-
- 4-(4-chloro-2-fluoroanilino)-7-(1,3-dioxolan-2-ylmethoxy)-6-methoxyquinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-morpholinobut-2-yn-1-yloxy)quinazoline,
- (E)-4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-morpholinobut-2-en-1-yloxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-7-(3-(2,6-dimethylmorpholino)propoxy)-6-methoxyquinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-([N-methyl-N-methylsulphonyl]amino)propoxy)quinazoline,
- 7-(2-[N-tert-butoxycarbonylamino]ethoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline,
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-([N-methyl-N-methylsulphonyl]amino)propoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-2-oxoimidazolidin-1-yl)ethoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(3-oxomorpholino)ethoxy)quinazoline and
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(3-oxomorpholino)ethoxy)quinazoline and salts thereof especially hydrochloride salts thereof.
-
- 4-(4-chloro-2-fluoroanilino-6-methoxy-7-(2-thiomorpholinoethoxy)quinazoline,
- (S)-4-(4-bromo-2-fluoroanilino)-7-(3-(2-carbamoylpyrrolidin-1-yl)propoxy)-6-methoxyquinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(2oxopyrrolidin-1-yl)propoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-oxopyrrolidin-1-yl)ethoxy)quinazoline,
- (S)-7-(3-(2-carbamoylpyrrolidin-1-yl)propoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-morpholinoethoxy)ethoxy)quinazoline and
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-(2-oxopyrrolidin-1-yl)propoxy)quinazoline and salts thereof especially hydrochloride salts thereof.
-
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)quinazoline and
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-3-yl)methoxyquinazoline and salts thereof especially hydrochloride salts thereof.
-
- 4-(4-bromo-2-fluoroanilino)-7-(3-(1,1-dioxothiomorpholino)propoxy)-6-methoxyquinazoline,
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-pyrrolidin-1-ylethoxy)ethoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-[4-methylpiperazin-1-yl]ethoxy)ethoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-morpholinopropylthio)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-([N-methyl-N-methoxyacetyl]amino)ethoxy)quinazoline and
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(2-oxopyrrolidin-1-yl)ethoxy)quinazoline and salts thereof especially hydrochloride salts thereof.
-
- (E)-4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-(pyrrolidin-1-yl)but-2-en-1-yloxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(methylsulphonyl)propoxy)quinazoline,
- (S)-4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-3-yl)methoxyquinazoline and
- (R)-4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-3-yl)methoxyquinazoline and salts thereof especially hydrochloride salts thereof, of which 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(methylsulphonyl)propoxy)quinazoline and salts thereof especially hydrochloride salts thereof, is more especially preferred.
-
- 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-2-methoxyethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-7-(2-(1,3-dioxolan-2-yl)ethoxy)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-7-(1,3-dioxolan-2-ylmethoxy)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-thiomorpholinoethoxy)quinazoline and salts thereof especially the hydrochloride salts thereof.
-
- (wherein R1, R2, X1 and R4 are as defined hereinbefore and L1 is a displaceable moiety), with a compound of the formula IV:
-
- (wherein R3 and m are as defined hereinbefore) whereby to obtain compounds of the formula I and salts thereof. A convenient displaceable moiety L1 is, for example, a halogeno, alkoxy (preferably C1-4alkoxy), aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.
-
- (wherein R3 and m are as hereinbefore defined) represents a phenyl group carrying one or more hydroxy groups, a compound of the formula I and salts thereof can be prepared by the deprotection of a compound of formula V:
-
- (wherein X1, m, R1, R2, R3 and 4 are as hereinbefore defined, P represents a phenolic hydroxy protecting group and pl is an integer from 1 to 5 equal to the number of protected hydroxy groups and such that m-pl is equal to the number of R3 substituents which are not protected hydroxy). The choice of phenolic hydroxy protecting group P is within the standard knowledge of an organic chemist, forexample those included in standard texts such as “Protective Groups in Organic Synthesis” T. W. Greene and R. G. M. Wuts, 2nd Ed. Wiley 1991, including ethers (for example, methyl, methoxymethyl, allyl and benzyl and benzyl substituted with up to two substituents selected from C1-4alkoxy and nitro), silyl ethers (for example, t-butyldiphenylsilyl and t-butyldimethylsilyl), esters (for example, acetate and benzoate) and carbonates (for example, methyl and benzyl and benzyl substituted with up to two substituents selected from C1-4alkoxy and nitro). The removal of such a phenolic hydroxy protecting group may be effected by any of the procedures known for such a transformation, including those reaction conditions indicated in standard texts such as that indicated hereinbefore, or by a related procedure. The reaction conditions preferably being such that the hydroxy derivative is produced without unwanted reactions at other sites within the starting or product compounds. For example, where the protecting group P is acetate, the transformation may conveniently be effected by treatment of the quinazoline derivative with a base as defined hereinbefore and including ammonia, and its mono and di-alkylated derivatives, preferably in the presence of a protic solvent or co-solvent such as water or an alcohol, for example methanol or ethanol. Such a reaction can be effected in the presence of an additional inert solvent or diluent as defined hereinbefore and at a temperature in the range 0 to 50° C., conveniently at about 20° C.
(c) Production of those compounds of formula I and salts thereof wherein the substituent X1 is —O—, —S— or —NR11— or —SO2—, —CONR8— or —SO2NR9— can be achieved by the reaction, conveniently in the presence of a base as defined hereinbefore, of a compound of the formula VI:
- (wherein X1, m, R1, R2, R3 and 4 are as hereinbefore defined, P represents a phenolic hydroxy protecting group and pl is an integer from 1 to 5 equal to the number of protected hydroxy groups and such that m-pl is equal to the number of R3 substituents which are not protected hydroxy). The choice of phenolic hydroxy protecting group P is within the standard knowledge of an organic chemist, forexample those included in standard texts such as “Protective Groups in Organic Synthesis” T. W. Greene and R. G. M. Wuts, 2nd Ed. Wiley 1991, including ethers (for example, methyl, methoxymethyl, allyl and benzyl and benzyl substituted with up to two substituents selected from C1-4alkoxy and nitro), silyl ethers (for example, t-butyldiphenylsilyl and t-butyldimethylsilyl), esters (for example, acetate and benzoate) and carbonates (for example, methyl and benzyl and benzyl substituted with up to two substituents selected from C1-4alkoxy and nitro). The removal of such a phenolic hydroxy protecting group may be effected by any of the procedures known for such a transformation, including those reaction conditions indicated in standard texts such as that indicated hereinbefore, or by a related procedure. The reaction conditions preferably being such that the hydroxy derivative is produced without unwanted reactions at other sites within the starting or product compounds. For example, where the protecting group P is acetate, the transformation may conveniently be effected by treatment of the quinazoline derivative with a base as defined hereinbefore and including ammonia, and its mono and di-alkylated derivatives, preferably in the presence of a protic solvent or co-solvent such as water or an alcohol, for example methanol or ethanol. Such a reaction can be effected in the presence of an additional inert solvent or diluent as defined hereinbefore and at a temperature in the range 0 to 50° C., conveniently at about 20° C.
-
- (wherein m, X1, R1, R2 and R3 are as hereinbefore defined) with a compound of formula VII:
R4—L1 (VII) - (wherein R4 and L1 are as hereinbefore defined); L1 is a displaceable moiety for example a halogeno or sulphonyloxy group such as a bromo or methanesulphonyloxy group. Conveniently L1 is a group O—+P(R52)3 (wherein R52 is butyl or phenyl) and in such cases the compound of formula VII is conveniently formed in situ. The reaction is preferably effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at about 50° C.
(d) Compounds of the formula I and salts thereof may be prepared by the reaction of a compound of the formula VIII:
- (wherein m, X1, R1, R2 and R3 are as hereinbefore defined) with a compound of formula VII:
-
- with a compound of the formula IX:
R4—X1—H (IX) - (wherein L1, R1, R2, R3, R4, m and X1 are all as hereinbefore defined). The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at about 100° C.
(e) Compounds of the formula I and salts thereof wherein R4 is C1-5alkylR53, [wherein R53 is selected from one of the following three groups: - 1) X7R27 (wherein X7 represents —O—, —S—, —SO2—, —NR54CO—, —NR55SO2— or —NR56— (wherein R54, R55 and R56 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R27 is as defined hereinbefore); and
- 2) X8C1-5alkylX3R16 (wherein X8 represents —O—, —S—, —SO2—, —NR57CO—, —NR58SO2— or NR59— (wherein R57, R58 and R59 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and X3 and R16 are as defined hereinbefore); and
- 3) X9C1-5alkylR33 (wherein X9 represents —O—, —S—, —SO2—, —NR60CO—, —NR61SO2— or NR62— (wherein R60, R61 and R62 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R33 is as defined hereinbefore);] may be prepared by reacting a compound of the formula X:
- with a compound of the formula IX:
-
- (wherein L1, X1, R1, R2, R3 and m are as hereinbefore defined and R63 is C1-5alkyl) with a compound of the formula XI:
R53—H (XI) - (wherein R53 is as defined hereinbefore) to give a compound of the formula I. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), and at a temperature in the range, for example 0 to 150° C., conveniently at about 50° C.
- (wherein L1, X1, R1, R2, R3 and m are as hereinbefore defined and R63 is C1-5alkyl) with a compound of the formula XI:
R45—H (XIa)
-
- (wherein R45 is as defined hereinbefore) to give a compound of the formula I. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), and at a temperature in the range, for example 0 to 150° C., conveniently at about 50° C.
(f) The production of those compounds of the formula I and salts thereof wherein the substituent R1 is represented by —NR5R6, where one or both of R5 and R6 are C1-3alkyl, may be effected by the reaction of compounds of formula I wherein the substituent R1 is an amino group and an alkylating agent, preferably in the presence of a base as defined hereinbefore. Such alkylating agents are C1-3alkyl moieties bearing a displaceable moiety as defined hereinbefore such as C1-3alkyl halides for example C1-3alkyl chloride, bromide or iodide. The reaction is preferably effected in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)) and at a temperature in the range, for example, 10 to 100° C., conveniently at about ambient temperature.
(g) The production of compounds of formula I and salts thereof wherein one or more of the substituents R1, R2 or R3 is an amino group may be effected by the reduction of a corresponding compound of formula I wherein the substituent(s) at the corresponding position(s) of the quinazoline and/or aniline ring is tare a nitro group(s). The reduction may conveniently be effected as described in process (i) hereinafter. The production of a compound of formula I and salts thereof wherein the substituent(s) at the corresponding position(s) of the quinazoline and/or aniline ring is/are a nitro group(s) may be effected by the processes described hereinbefore and hereinafter in processes (a-e) and (i-v) using a quinazoline compound selected from the compounds of the formulae (I-XXVII) in which the substituent(s) at the corresponding position(s) of the quinazoline and/or aniline ring is/are a nitro group(s).
- (wherein R45 is as defined hereinbefore) to give a compound of the formula I. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), and at a temperature in the range, for example 0 to 150° C., conveniently at about 50° C.
-
- (wherein R1, R2, R3 and X1 are as hereinbefore defined).
-
- (wherein R1, R2 and L1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at about 100° C.
-
- (wherein R1, R2, R4 and X1, are as hereinbefore defined, and A1 is an hydroxy, alkoxy (preferably C1-4alkoxy) or amino group) whereby to form a compound of formula XII or salt thereof. The cyclisation may be effected by reacting a compound of the formula XIV, where A1 is an hydroxy or alkoxy group, with formamide or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained, such as [3-(dimethylamino)-2-azaprop-2-enylidene]dimethylammonium chloride. The cyclisation is conveniently effected in the presence of formamide as solvent or in the presence of an inert solvent or diluent such as an ether for example 1,4-dioxan. The cyclisation is conveniently effected at an elevated temperature, preferably in the range 80 to 200° C. The compounds of formula XII may also be prepared by cyclising a compound of the formula XIV, where A1 is an amino group, with formic acid or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained. Equivalents of formic acid effective to cause cyclisation include for example a tri-C1-4alkoxymethane, for example triethoxymethane and trimethoxymethane. The cyclisation is conveniently effected in the presence of a catalytic amount of an anhydrous acid, such as a sulphonic acid for example p-toluenesulphonic acid, and in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as diethylether or tetrahydrofuran, or an aromatic hydrocarbon solvent such as toluene. The cyclisation is conveniently effected at a temperature in the range, for example 10 to 100° C., preferably in the range 20 to 50° C.
-
- (wherein R1, R2, R4, X1 and A1 are as hereinbefore defined) to yield a compound of formula XIV as hereinbefore defined. The reduction of the nitro group may conveniently be effected by any of the procedures known for such a transformation. The reduction may be carried out, for example, by the hydrogenation of a solution of the nitro compound in the presence of an inert solvent or diluent as defined hereinbefore in the presence of a metal effective to catalyse hydrogenation reactions such as palladium or platinum. A further reducing agent is, for example, an activated metal such as activated iron (produced for example by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be effected by heating the nitro compound and the activated metal in the presence of a solvent or diluent such as a mixture of water and alcohol, for example methanol or ethanol, to a temperature in the range, for example 50 to 150° C., conveniently at about 70° C.
-
- (wherein R1, R2, L1 and A1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined to give a compound of the formula XV. The reaction of the compounds of formulae XVI and IX is conveniently effected under conditions as described for process (d) hereinbefore.
-
- (wherein R1, R2, X1 and A1 are as hereinbefore defined with the proviso that X1 is not —CH2—) with a compound of the formula VII as hereinbefore defined to yield a compound of formula XV as hereinbefore defined. The reaction of the compounds of formulae XVII and VII is conveniently effected under conditions as described for process (c) hereinbefore.
-
- (wherein R1, R2 and X1 are as hereinbefore defined with the proviso that X1 is not —CH2— and L2 represents a displaceable protecting moiety) with a compound of the formula VII as hereinbefore defined, whereby to obtain a compound of formula III in which L1 is represented by L2.
-
- (wherein R1, R2, P, X1 and L2 are as hereinbefore defined with the proviso that X1 is not —CH2—). Deprotection may be effected by techniques well known in the literature, for example where P represents a benzyl group deprotection may be effected by hydrogenolysis or by treatment with trifluoroacetic acid.
-
- (wherein R3, m, pl and P are as hereinbefore defined). The reaction may for example be effected as described for process (a) hereinbefore.
-
- (wherein R1, R2, L1, R3, m, pl and P are as hereinbefore defined) with a compound of formula IX as hereinbefore defined. The reaction may for example be effected as described for process (d) above.
-
- (wherein R1, R2, R3, X1, P, pl and m are as hereinbefore defined with the proviso that X1 is not —CH2—) with a compound of the formula VII as hereinbefore defined. The reaction may for example be effected as described for process (c) hereinbefore.
-
- (wherein R1, R2, and L1 are as hereinbefore defined, and L1 in the 4 and 7-positions may be the same or different) with a compound of the formula XX as hereinbefore defined. The reaction may be effected for example by a process as described in (a) above.
-
- (wherein R1, R2, R3, P, X1, pl and m are as hereinbefore defined with the proviso that X1 is not —CH2—) and tie-in deprotecting the compound of formula XXIV for example as described in (i) above.
(iii) Compounds of the formula VI as hereinbefore defined and salts thereof may be made by deprotecting the compound of formula XXV:
- (wherein R1, R2, R3, P, X1, pl and m are as hereinbefore defined with the proviso that X1 is not —CH2—) and tie-in deprotecting the compound of formula XXIV for example as described in (i) above.
-
- (wherein R1, R2, R3, P, X1 and m are as hereinbefore defined) by a process for example as described in (i) above.
L1—R63—L1 (XXVI)
-
- (wherein L1 and R63 are as hereinbefore defined) to give a compound of the formula X. The reaction may be effected for example by a process as described in (c) above.
-
- (wherein L1, R63, X1, R1, R2, R3, P, m and p1 are as defined hereinbefore) by a process for example as described in (b) above.
-
- (i) other antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example linomide, inhibitors of integrin αvβ3 function, angiostatin, razoxin, thalidomide);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5α-dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); and
- (iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan).
-
- [(i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at ambient temperature, that is in the range 18-25° C. and under an atmosphere of an inert gas such as argon;
- (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany;
- (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus, an oil-bath apparatus or a Koffler hot plate apparatus.
- (vi) the structures of the end-products of the formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, muitiplet; br, broad; q, quartet;
- (vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;
- (viii) the following abbreviations have been used:
- DMF N,N-dimethylformamide
- DMSO dimethylsulphoxide
- THF tetrahydrofuran
- TFA trifluoroacetic acid
- NMP 1-methyl-2-pyrrolidinone.]
(a) | Tablet I | mg/tablet |
Compound X | 100 | |
Lactose Ph. Eur | 182.75 | |
Croscarmellose sodium | 12.0 | |
Maize starch paste (5% w/v paste) | 2.25 | |
Magnesium stearate | 3.0 | |
(b) | Tablet II | mg/tablet |
Compound X | 50 | |
Lactose Ph. Eur | 223.75 | |
Croscarmellose sodium | 6.0 | |
Maize starch | 15.0 | |
Polyvinylpyrrolidone (5% w/v paste) | 2.25 | |
Magnesium stearate | 3.0 | |
(c) | Tablet III | mg/tablet |
Compound X | 1.0 | |
Lactose Ph. Eur | 93.25 | |
Croscarmellose sodium | 4.0 | |
Maize starch paste (5% w/v paste) | 0.75 | |
Magnesium stearate | 1.0 | |
(d) | Capsule | mg/capsule |
Compound X | 10 | |
Lactose Ph. Eur | 488.5 | |
Magnesium stearate | 1.5 | |
(e) | Injection I | (50 mg/ml) |
Compound X | 5.0% | w/v | |
1N Sodium hydroxide solution | 15.0% | v/v | |
0.1N Hydrochloric acid | |||
(to adjust pH to 7.6) | |||
Polyethylene glycol 400 | 4.5% | w/v | |
Water for injection to 100% | |||
(f) | Injection II | 10 mg/ml) |
Compound X | 1.0% | w/v | |
Sodium phosphate BP | 3.6% | w/v | |
0.1N Sodium hydroxide solution | 15.0% | v/v | |
Water for injection to 100 | |||
(g) | Injection III | (1 mg/ml, buffered to pH 6) |
Compound X | 0.1% | w/v | |
Sodium phosphate BP | 2.26% | w/v | |
Citric acid | 0.38% | w/v | |
Polyethylene glycol 400 | 3.5% | w/v | |
Water for injection to 100% | |||
Note | |||
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. |
Claims (23)
R4—L1 (VII)
R4—X1—H (IX)
R53—H (XI)
R45—H (XIa)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96402033 | 1996-09-25 | ||
EP96402033 | 1996-09-25 | ||
EP97401042 | 1997-05-09 | ||
EP97401042 | 1997-05-09 | ||
PCT/GB1997/002588 WO1998013354A1 (en) | 1996-09-25 | 1997-09-23 | Quinazoline derivatives and pharmaceutical compositions containing them |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/269,595 Reissue US6414148B1 (en) | 1996-09-25 | 1997-09-23 | Quinazoline derivatives and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE42353E1 true USRE42353E1 (en) | 2011-05-10 |
Family
ID=26144073
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/269,595 Ceased US6414148B1 (en) | 1996-09-25 | 1997-09-23 | Quinazoline derivatives and pharmaceutical compositions containing them |
US12/170,027 Expired - Lifetime USRE42353E1 (en) | 1996-09-25 | 1997-09-23 | Quinazoline derivatives and pharmaceutical compositions containing them |
US10/080,716 Expired - Lifetime US6673803B2 (en) | 1996-09-25 | 2002-02-25 | Quinazoline derivatives and pharmaceutical compositions containing them |
US10/698,388 Expired - Lifetime US6897210B2 (en) | 1996-09-25 | 2003-11-03 | Quinazoline derivatives and pharmaceutical compositions containing them |
US11/024,840 Abandoned US20050239777A1 (en) | 1996-09-25 | 2004-12-30 | Quinazoline derivatives and pharmaceutical compositions containing them |
US12/766,106 Abandoned US20110071144A1 (en) | 1996-09-25 | 2010-04-23 | Quinazoline derivatives and pharmaceutical compositions containing them |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/269,595 Ceased US6414148B1 (en) | 1996-09-25 | 1997-09-23 | Quinazoline derivatives and pharmaceutical compositions containing them |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/080,716 Expired - Lifetime US6673803B2 (en) | 1996-09-25 | 2002-02-25 | Quinazoline derivatives and pharmaceutical compositions containing them |
US10/698,388 Expired - Lifetime US6897210B2 (en) | 1996-09-25 | 2003-11-03 | Quinazoline derivatives and pharmaceutical compositions containing them |
US11/024,840 Abandoned US20050239777A1 (en) | 1996-09-25 | 2004-12-30 | Quinazoline derivatives and pharmaceutical compositions containing them |
US12/766,106 Abandoned US20110071144A1 (en) | 1996-09-25 | 2010-04-23 | Quinazoline derivatives and pharmaceutical compositions containing them |
Country Status (33)
Country | Link |
---|---|
US (6) | US6414148B1 (en) |
EP (1) | EP0929530B1 (en) |
JP (3) | JP3438818B2 (en) |
KR (1) | KR100618065B1 (en) |
CN (1) | CN1142920C (en) |
AT (1) | ATE228114T1 (en) |
AU (1) | AU729968C (en) |
BR (1) | BR9711302B1 (en) |
CA (1) | CA2263319C (en) |
CH (1) | CH0929530H1 (en) |
CL (1) | CL2004001178A1 (en) |
CY (1) | CY2453B1 (en) |
CZ (1) | CZ296962B6 (en) |
DE (1) | DE69717294C5 (en) |
DK (1) | DK0929530T3 (en) |
ES (1) | ES2185999T3 (en) |
GB (1) | GB9718972D0 (en) |
HK (1) | HK1019332A1 (en) |
HU (1) | HU228176B1 (en) |
IL (1) | IL129038A (en) |
MY (1) | MY129540A (en) |
NO (1) | NO313138B1 (en) |
NZ (1) | NZ334014A (en) |
PL (1) | PL190326B1 (en) |
PT (1) | PT929530E (en) |
RU (1) | RU2198879C2 (en) |
SI (1) | SI0929530T1 (en) |
SK (1) | SK283175B6 (en) |
TR (1) | TR199900674T2 (en) |
TW (1) | TW520364B (en) |
UA (1) | UA57752C2 (en) |
WO (1) | WO1998013354A1 (en) |
ZA (1) | ZA978553B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100029627A1 (en) * | 2006-07-12 | 2010-02-04 | Alexandra Papanikos | Mtki quinazoline derivatives |
US20100152174A1 (en) * | 2004-12-08 | 2010-06-17 | Eddy Jean Edgard Freyne | Macrocyclic quinazole derivatives and their use as mtki |
US20100173913A1 (en) * | 2003-12-18 | 2010-07-08 | Janssen Pharmaceutica N.V. | Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents |
US8318731B2 (en) | 2007-07-27 | 2012-11-27 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
WO2015031604A1 (en) | 2013-08-28 | 2015-03-05 | Crown Bioscience, Inc. | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
US9040548B2 (en) | 1999-11-05 | 2015-05-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
US9688691B2 (en) | 2004-12-08 | 2017-06-27 | Janssen Pharmaceutica Nv | Macrocyclic quinazole derivatives and their use as MTKI |
US10011587B2 (en) | 2014-05-15 | 2018-07-03 | The Methodist Hospital System | Multivalent ligands targeting VEGFR |
Families Citing this family (426)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
DE69733825T2 (en) | 1996-09-25 | 2006-06-08 | Astrazeneca Ab | CHINOLIN DERIVATIVES VEZÖGERN THE EFFECT OF GROWTH FACTORS SUCH AS VEGF |
DE69838172T2 (en) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
WO2000017197A1 (en) * | 1998-09-21 | 2000-03-30 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
CN1341104A (en) | 1999-02-27 | 2002-03-20 | 贝林格尔英格海姆法玛公司 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
DE19911509A1 (en) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
RS49836B (en) * | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Process and intermediates for preparing anti-cancer compounds |
AU775285B2 (en) | 1999-06-21 | 2004-07-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
WO2001004111A1 (en) * | 1999-07-09 | 2001-01-18 | Glaxo Group Limited | Anilinoquinazolines as protein tyrosine kinase inhibitors |
WO2001021596A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
SE9903544D0 (en) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
UA74803C2 (en) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
US6706731B2 (en) | 2000-02-09 | 2004-03-16 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
US7498335B2 (en) * | 2000-03-06 | 2009-03-03 | Astrazeneca Ab | Method of producing an antiangiogenic or vascular permeability reducing effect |
US20070021392A1 (en) * | 2000-03-31 | 2007-01-25 | Davis Peter D | Divided dose therapies with vascular damaging activity |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
JP4970689B2 (en) * | 2000-04-07 | 2012-07-11 | アストラゼネカ アクチボラグ | Quinazoline compounds |
UA73993C2 (en) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
AR028948A1 (en) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | NEW COMPOUNDS |
CA2419301C (en) * | 2000-08-21 | 2009-12-08 | Astrazeneca Ab | Quinazoline derivatives |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE10042061A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
DE10042058A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
EP1326859A1 (en) * | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Quinazoline derivatives with anti-tumour activity |
SE0003828D0 (en) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
JP4564713B2 (en) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Nitrogen heterocyclic compounds, and methods for making nitrogen heterocyclic compounds and intermediates thereof |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
ES2312557T3 (en) | 2001-04-19 | 2009-03-01 | Astrazeneca Ab | DERIVATIVES OF QUINAZOLINA. |
WO2002092577A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
WO2003000188A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0128108D0 (en) * | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
GB0128109D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
AU2003202094B2 (en) * | 2002-02-01 | 2009-10-08 | Astrazeneca Ab | Quinazoline compounds |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE10221018A1 (en) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
DE60327323D1 (en) * | 2002-07-09 | 2009-06-04 | Astrazeneca Ab | CHINAZOLINE DERIVATIVE AND ITS APPLICATION IN CANCER TREATMENT |
AU2003249212C1 (en) * | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
WO2004018435A1 (en) | 2002-08-24 | 2004-03-04 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
JP4593464B2 (en) * | 2002-11-04 | 2010-12-08 | アストラゼネカ アクチボラグ | Quinazoline derivatives as Src tyrosine kinase inhibitors |
ATE438644T1 (en) | 2002-12-24 | 2009-08-15 | Astrazeneca Ab | CHINAZOLINE DERIVATIVES |
DE602004009295T2 (en) | 2003-01-14 | 2008-07-03 | Arena Pharmaceuticals, Inc., San Diego | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM FOR THE PREVENTION AND TREATMENT OF METABOLISM-CONDITIONAL DISEASES SUCH AS DIABETES OR HYPERGLYKEMIA |
US7223749B2 (en) * | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
PA8603801A1 (en) * | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | DERIVATIVES OF QUINAZOLINE |
SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
KR20060033782A (en) * | 2003-07-10 | 2006-04-19 | 아스트라제네카 아베 | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
GB0316176D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
AR045047A1 (en) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
GB0318423D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
CA2876822C (en) | 2003-08-27 | 2015-11-17 | David Shima | Combination therapy for the treatment of ocular neovascular disorders |
PL1667991T3 (en) | 2003-09-16 | 2008-12-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
JP2007505871A (en) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | Quinazoline derivatives |
BRPI0414532B1 (en) * | 2003-09-19 | 2018-06-05 | Astrazeneca Ab | QUINAZOLIN DERIVATIVE COMPOUND, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION, AND USE OF A QUINAZOLIN DERIVATIVE COMPOUND |
WO2005028470A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0414735A (en) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | quinazoline derivative, compound, pharmaceutical composition, use of quinazoline derivative, method for producing an antiproliferative effect on a warm-blooded animal, and process for the preparation of a quinazoline derivative |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
EP2213661B1 (en) * | 2003-09-26 | 2011-07-20 | Exelixis Inc. | c-Met Modulators and Methods of Use |
US7456189B2 (en) * | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
WO2005066163A2 (en) | 2004-01-05 | 2005-07-21 | Astrazeneca Ab | Thiophene derivatives as chk 1 inihibitors |
WO2005075439A1 (en) | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Quinazoline derivatives |
DK1746999T3 (en) | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
GB0411378D0 (en) * | 2004-05-21 | 2004-06-23 | Astrazeneca Ab | Pharmaceutical compositions |
SE0401657D0 (en) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
CN101031551A (en) * | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
MX2007002240A (en) | 2004-08-28 | 2007-04-20 | Astrazeneca Ab | Pyrimidine sulphonamide derivatives as chemokine receptor modulators. |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
JP4881875B2 (en) | 2004-12-14 | 2012-02-22 | アストラゼネカ アクチボラグ | Pyrazolopyrimidine compounds as antitumor agents |
CA2595610C (en) | 2004-12-21 | 2013-03-05 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
EP1844023A1 (en) * | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
DOP2006000010A (en) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | PROCEDURE TO PREPARE AROMATIC ETERES |
CN101155800B (en) | 2005-02-04 | 2012-05-23 | 阿斯利康(瑞典)有限公司 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
AU2006217738A1 (en) * | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
US20080240926A1 (en) * | 2005-03-28 | 2008-10-02 | Toshiharu Kobayashi | Cobalt-Free Ni-Base Superalloy |
WO2006119675A1 (en) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease |
WO2006119676A1 (en) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease |
WO2006119674A1 (en) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease |
WO2006119673A1 (en) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease |
CN101626767A (en) | 2005-05-18 | 2010-01-13 | 阵列生物制药公司 | The heterocycle inhibitor of MEK and using method thereof |
BRPI0613563A2 (en) | 2005-07-21 | 2012-01-17 | Astrazeneca Ab | new piperidine derivatives |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
JP2009508918A (en) | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 4- (1H-indazol-5-yl] amino) quinazoline compounds as erbB receptor tyrosine kinase inhibitors for cancer therapy |
EP1939199A4 (en) | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
EP1939200A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
WO2007034817A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
WO2007034917A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
US20090192153A1 (en) | 2005-09-22 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
US8148572B2 (en) | 2005-10-06 | 2012-04-03 | Astrazeneca Ab | Compounds |
AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
CA2626375A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
CA2629244C (en) | 2005-11-11 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
CA2632194C (en) | 2005-11-15 | 2012-01-03 | Array Biopharma Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
TW200730512A (en) | 2005-12-12 | 2007-08-16 | Astrazeneca Ab | Novel compounds |
ATE552853T1 (en) | 2005-12-13 | 2012-04-15 | Medimmune Ltd | PROTEINS THAT SPECIFICALLY BIND INSULIN-LIKE GROWTH FACTORS AND THEIR APPLICATIONS |
TW200732296A (en) | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Novel compounds |
US20070213319A1 (en) * | 2006-01-11 | 2007-09-13 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
EP2125722A2 (en) | 2006-05-26 | 2009-12-02 | AstraZeneca AB | Bi-aryl or aryl-heteroaryl substituted indoles |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
DE102006037478A1 (en) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2- (Heterocyclylbenzyl) -pyridazinone derivatives |
MX2009001946A (en) | 2006-08-23 | 2009-03-05 | Kudos Pharm Ltd | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors. |
JP5580592B2 (en) * | 2006-09-11 | 2014-08-27 | キュリス,インコーポレイテッド | Quinazoline-based EGFR inhibitors containing zinc binding moieties |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
JP2010502743A (en) * | 2006-09-11 | 2010-01-28 | キュリス,インコーポレイテッド | Multifunctional small molecules as antiproliferative drugs |
AU2007296745B2 (en) * | 2006-09-11 | 2011-12-01 | Curis, Inc. | Quinazoline based EGFR inhibitors |
US8877764B2 (en) * | 2006-09-18 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
ES2399768T3 (en) | 2006-09-29 | 2013-04-03 | Astrazeneca Ab | Combination of ZD6474 and bevacizumab for cancer therapy |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
US7799954B2 (en) | 2006-11-17 | 2010-09-21 | Abraxis Bioscience, Llc | Dicarbonyl derivatives and methods of use |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
JP4604129B2 (en) | 2006-12-19 | 2010-12-22 | アストラゼネカ・アクチエボラーグ | Quinuclidinol derivatives as muscarinic receptor antagonists |
CL2008000191A1 (en) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER. |
EA200901041A1 (en) * | 2007-02-06 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
TW200902018A (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
DE102007025717A1 (en) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Aryl ether pyridazinone derivatives |
DE102007025718A1 (en) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | pyridazinone derivatives |
DE102007026341A1 (en) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
UA100983C2 (en) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Biphenyloxypropanoic acid as crth2 modulator and intermediates |
DE102007032507A1 (en) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | pyridazinone derivatives |
DE102007038957A1 (en) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-thioxo-pyridazine derivatives |
DE102007041115A1 (en) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
US8119616B2 (en) * | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
EP2207788A1 (en) | 2007-10-04 | 2010-07-21 | AstraZeneca AB | Steroidal [3, 2-c]pyrazole compounds, with glucocorticoid activity |
TWI453021B (en) | 2007-10-11 | 2014-09-21 | Astrazeneca Ab | Novel protein kinase b inhibitors |
MX2010004625A (en) | 2007-10-29 | 2010-05-20 | Natco Pharma Ltd | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents. |
CN101945870B (en) | 2007-12-19 | 2012-10-03 | 健泰科生物技术公司 | 5-anilinoimidazopyridines and methods of use |
MX343594B (en) | 2007-12-21 | 2016-11-11 | Medimmune Ltd | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ra) - 173. |
US8486963B2 (en) | 2007-12-21 | 2013-07-16 | Genentech, Inc. | Azaindolizines and methods of use |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE102007061963A1 (en) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | pyridazinone derivatives |
ATE554076T1 (en) * | 2008-01-17 | 2012-05-15 | Bayer Pharma AG | SULFOXIMINE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE MODULATORS, THEIR PRODUCTION AND THEIR USE AS MEDICATIONS |
AU2009211523B2 (en) | 2008-02-07 | 2014-03-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
AU2009215375A1 (en) * | 2008-02-21 | 2009-08-27 | Astrazeneca Ab | Combination therapy 238 |
ES2401550T3 (en) | 2008-02-28 | 2013-04-22 | Merck Patent Gmbh | Protein kinase inhibitors and use thereof |
DE102008019907A1 (en) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | pyridazinone derivatives |
JP5739802B2 (en) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | 4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate |
DK2297106T3 (en) | 2008-05-27 | 2014-10-06 | Astrazeneca Ab | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN TREATMENT OF PDE4-MEDIATED DISEASES |
DE102008025750A1 (en) | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | Dihydropyrazolderivate |
DE102008028905A1 (en) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives |
DE102008029734A1 (en) | 2008-06-23 | 2009-12-24 | Merck Patent Gmbh | Thiazolyl-piperidine derivatives |
US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
US8492427B2 (en) | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
UY31952A (en) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-METHYLIDENE-1,3-THIAZOLIDINE-2,4-DIONAS REPLACED AS PIM QUINASE INHIBITORS |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
DE102008037790A1 (en) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclic triazole derivatives |
DE102008038221A1 (en) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-azaindole derivatives |
CN101659657B (en) * | 2008-08-29 | 2014-05-14 | 北大方正集团有限公司 | Quinoline substituted by cyan and preparation method and applications thereof |
CN101659658B (en) * | 2008-08-29 | 2014-04-02 | 北大方正集团有限公司 | Quinoline substituted by cyan |
EP2927244A1 (en) | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
DE102008052943A1 (en) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | azaindole derivatives |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
US7863325B2 (en) | 2008-12-11 | 2011-01-04 | Axcentua Pharmaceuticals Ab | Crystalline genistein sodium salt dihydrate |
US9012495B2 (en) | 2008-12-11 | 2015-04-21 | Axcentua Pharmaceuticals Ab | Crystalline forms of genistein |
US20100152197A1 (en) | 2008-12-15 | 2010-06-17 | Astrazeneca Ab | (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives |
AU2009333653B2 (en) | 2008-12-17 | 2015-09-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
ES2603208T3 (en) | 2008-12-18 | 2017-02-24 | Merck Patent Gmbh | Tricyclic azaindoles |
DE102008063667A1 (en) | 2008-12-18 | 2010-07-01 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives |
DE102008062826A1 (en) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | pyridazinone derivatives |
DE102008062825A1 (en) | 2008-12-23 | 2010-06-24 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives |
EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
DE102009003954A1 (en) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | pyridazinone derivatives |
DE102009003975A1 (en) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
DE102009004061A1 (en) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | pyridazinone derivatives |
TWI641593B (en) | 2009-01-16 | 2018-11-21 | 美商艾克塞里克斯公司 | Pharmaceutical composition comprising malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and use thereof |
MX368362B (en) | 2009-02-05 | 2019-09-30 | Immunogen Inc | Novel benzodiazepine derivatives. |
WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
GB0905127D0 (en) | 2009-03-25 | 2009-05-06 | Pharminox Ltd | Novel prodrugs |
UY32520A (en) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
SI2451445T1 (en) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
DE102009043260A1 (en) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolone derivatives |
CA2775601C (en) | 2009-09-28 | 2017-10-03 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
KR20120099639A (en) | 2009-10-02 | 2012-09-11 | 아스트라제네카 아베 | 2-pyridone compounds used as inhibitors of neutrophil elastase |
DE102009049679A1 (en) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
CA2777746C (en) | 2009-11-18 | 2019-05-14 | Astrazeneca Ab | Benzoimidazole compounds and uses thereof |
KR101790767B1 (en) | 2009-11-24 | 2017-10-26 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
KR20120093428A (en) | 2009-12-14 | 2012-08-22 | 메르크 파텐트 게엠베하 | Sphingosine kinase inhibitors |
DE102009058280A1 (en) | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | thiazole |
SG181643A1 (en) | 2009-12-17 | 2012-07-30 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
WO2011085641A1 (en) | 2010-01-15 | 2011-07-21 | Suzhou Neupharma Co., Ltd. | Certain chemical entities, compositions, and methods |
MX2012008328A (en) | 2010-01-19 | 2012-08-08 | Astrazeneca Ab | Pyrazine derivatives. |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
TWI406853B (en) * | 2010-04-07 | 2013-09-01 | Dev Center Biotechnology | Dual inhibitors of egfr and vegfr-2 and uses and production processes thereof |
WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
KR101217526B1 (en) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof |
WO2012000182A1 (en) * | 2010-06-30 | 2012-01-05 | Hutchison Medipharma Limited | Quinazoline compounds |
TW201219383A (en) | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
TWI535712B (en) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | Chemical compounds |
DE102010034699A1 (en) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | pyrimidine derivatives |
CN102656179B (en) | 2010-08-28 | 2015-07-29 | 苏州润新生物科技有限公司 | Bufalin derivative, its pharmaceutical composition and purposes |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
GB201016442D0 (en) | 2010-09-30 | 2010-11-17 | Pharminox Ltd | Novel acridine derivatives |
DE102010048800A1 (en) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | quinoxaline |
DE102010049595A1 (en) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | quinazoline derivatives |
WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
JP2013542916A (en) | 2010-11-19 | 2013-11-28 | 大日本住友製薬株式会社 | Cyclic amide compounds and their use in the treatment of diseases |
WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
ES2575688T3 (en) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy |
JP5978226B2 (en) | 2010-12-17 | 2016-08-24 | 大日本住友製薬株式会社 | Purine derivatives |
BR112013015508B1 (en) | 2010-12-20 | 2022-04-05 | Medimmune Limited | Antibody molecule to human il-18, isolated vh domain and isolated vl domain, composition, use of an antibody molecule or isolated vh domain and isolated vl domain, isolated nucleic acid molecule, recombinant prokaryotic host cell, method for producing an antibody, and in vitro method for measuring il-18 in a sample from an individual |
EP2670763B1 (en) | 2011-02-02 | 2018-08-01 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
EP3666289A1 (en) | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
EP2675794B1 (en) | 2011-02-17 | 2019-02-13 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
JP6006242B2 (en) * | 2011-03-04 | 2016-10-12 | ニューゲン セラピューティクス, インコーポレイテッド | Alkyne-substituted quinazoline compounds and methods of use |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
UY34013A (en) | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ? CHROMENONE COMPOUNDS WITH ANTI-TUMORAL ACTIVITY ?. |
WO2012155339A1 (en) | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof |
KR101317809B1 (en) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
WO2012175991A1 (en) | 2011-06-24 | 2012-12-27 | Pharminox Limited | Fused pentacyclic anti - proliferative compounds |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
MX342874B (en) | 2011-07-12 | 2016-10-17 | Astrazeneca Ab | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator. |
SG10201910984XA (en) | 2011-07-27 | 2020-01-30 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
DE102011111400A1 (en) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclic heteroaromatic compounds |
US9295671B2 (en) | 2011-08-26 | 2016-03-29 | Neupharma, Inc. | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer |
EP2753174A4 (en) | 2011-09-01 | 2015-05-20 | Xiangping Qian | Certain chemical entities, compositions, and methods |
JP6093768B2 (en) | 2011-09-14 | 2017-03-08 | ニューファーマ, インコーポレイテッド | Specific chemical entities, compositions and methods |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
US20140235573A1 (en) | 2011-09-29 | 2014-08-21 | The University Of Liverpool | Prevention and/or treatment of cancer and/or cancer metastasis |
US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CA2862694C (en) | 2012-01-28 | 2020-07-28 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
PT2812323T (en) | 2012-02-09 | 2016-07-13 | Merck Patent Gmbh | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors |
WO2013117285A1 (en) | 2012-02-09 | 2013-08-15 | Merck Patent Gmbh | Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors |
AU2013224420B2 (en) | 2012-02-21 | 2016-12-15 | Merck Patent Gmbh | Furopyridine derivatives |
EP2817306B1 (en) | 2012-02-21 | 2015-09-16 | Merck Patent GmbH | Cyclic diaminopyrimidine derivatives as syk inhibitors |
EP2817310B1 (en) | 2012-02-21 | 2018-03-21 | Merck Patent GmbH | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
JP6049768B2 (en) | 2012-03-07 | 2016-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Triazolopyrazine derivatives |
EP2752413B1 (en) | 2012-03-26 | 2016-03-23 | Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences | Quinazoline derivative and application thereof |
PL2831077T3 (en) | 2012-03-28 | 2016-10-31 | Bicyclic pyrazinone derivatives | |
WO2013144532A1 (en) | 2012-03-30 | 2013-10-03 | Astrazeneca Ab | 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents |
EP2834273B1 (en) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
EP2852285B1 (en) | 2012-04-29 | 2018-08-08 | Neupharma, Inc. | Bufadienolide compounds substituted in position 3 by a heterocyclic amine for use in the treatment of cancer |
CN104271580B (en) | 2012-05-04 | 2017-02-22 | 默克专利股份公司 | Pyrrolotriazinone derivatives |
EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
GB201211021D0 (en) | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
ES2611788T3 (en) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates thereof, methods for their preparation and methods for use |
CN104507957B (en) | 2012-07-24 | 2018-12-25 | 默克专利股份有限公司 | For treating the hydroxyl statin derivative of arthropathy |
JP6374384B2 (en) | 2012-08-07 | 2018-08-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Pyridopyrimidine derivatives as protein kinase inhibitors |
PL2882714T3 (en) | 2012-08-08 | 2020-02-28 | Merck Patent Gmbh | (aza-)isoquinolinone derivatives |
CA2882158A1 (en) | 2012-08-17 | 2014-02-20 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
SG11201501464TA (en) | 2012-08-31 | 2015-03-30 | Sutro Biopharma Inc | Modified amino acids comprising an azido group |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9388142B2 (en) | 2012-09-26 | 2016-07-12 | Merck Patent Gmbh | Quinazolinone derivatives as PARP inhibitors |
EP2911692B1 (en) | 2012-10-26 | 2019-08-21 | The University of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
WO2014066955A1 (en) | 2012-11-05 | 2014-05-08 | Lindley Robyn Alice | Methods for determining the cause of somatic mutagenesis |
EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CA2891484A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | 3-aminocyclopentane carboxamide derivatives |
KR20140096571A (en) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one |
AU2014211962B2 (en) | 2013-01-31 | 2017-11-16 | Bellus Health Cough Inc. | Imidazopyridine compounds and uses thereof |
EP2958901B1 (en) | 2013-02-25 | 2016-11-02 | Merck Patent GmbH | 2-amino-3,4-dihydro-quinazoline derivatives and their use as cathepsin d inhibitors |
US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP3566750A3 (en) | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6409007B2 (en) | 2013-03-05 | 2018-10-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 9- (Aryl or heteroaryl) -2- (pyrazolyl, pyrrolidinyl or cyclopentyl) aminopurine derivatives as anticancer agents |
WO2014144227A1 (en) | 2013-03-15 | 2014-09-18 | Magceutics, Inc. | Magnesium compositions and uses thereof for cancers |
WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US20160115146A1 (en) | 2013-06-07 | 2016-04-28 | Universite Catholique De Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
SG11201510369WA (en) | 2013-06-25 | 2016-01-28 | Univ Canberra | Methods and compositions for modulating cancer stem cells |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP3508204A1 (en) | 2013-08-23 | 2019-07-10 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
ES2851724T3 (en) | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Stem cell modulation |
US20160298197A1 (en) | 2013-10-01 | 2016-10-13 | Queensland University Of Technology | Kits and methods for diagnosis, screening, treatment and disease monitoring |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
CN105330653A (en) * | 2014-08-11 | 2016-02-17 | 石药集团中奇制药技术(石家庄)有限公司 | Quinazoline derivatives |
CA2958704A1 (en) | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
AU2015349613B2 (en) | 2014-11-17 | 2022-01-13 | The Council Of The Queensland Institute Of Medical Research | Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof |
MA41179A (en) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | PARG INHIBITOR COMPOUNDS |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
CN107613769A (en) | 2015-02-17 | 2018-01-19 | 润新生物公司 | Some chemical entities, composition and method |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
BR112017027656B1 (en) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF |
AU2016302384B2 (en) | 2015-08-04 | 2020-07-16 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
WO2017031551A1 (en) | 2015-08-26 | 2017-03-02 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US11708413B2 (en) | 2016-01-27 | 2023-07-25 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
AU2017214761B2 (en) | 2016-02-01 | 2024-02-01 | Epiaxis Therapeutics Pty Ltd | Proteinaceous compounds and uses therefor |
GB201604182D0 (en) | 2016-03-11 | 2016-04-27 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
BR112018068347A2 (en) | 2016-03-21 | 2019-01-15 | Astrazeneca Ab | cinolin-4-amine compounds and their use in cancer treatment |
SG11201807040WA (en) | 2016-04-07 | 2018-09-27 | Astrazeneca Ab | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer |
CN105853434A (en) * | 2016-04-13 | 2016-08-17 | 李春 | Medicinal composition for treating gingivitis in orthodontic children |
ES2925698T3 (en) | 2016-04-15 | 2022-10-19 | Cancer Research Tech Ltd | Heterocyclic compounds as RET kinase inhibitors |
GB2554333A (en) | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
GB201608227D0 (en) | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
DK3490565T3 (en) | 2016-07-29 | 2022-07-11 | Rapt Therapeutics Inc | AZETIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF |
US10544106B2 (en) | 2016-08-15 | 2020-01-28 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018055402A1 (en) | 2016-09-22 | 2018-03-29 | Cancer Research Technology Limited | Preparation and uses of pyrimidinone derivatives |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
BR112019011284A2 (en) | 2016-12-05 | 2019-10-22 | Apros Therapeutics Inc | compound, pharmaceutical composition, methods of treating a condition, hbv and cancer, and, use of a compound. |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
US10407446B2 (en) | 2016-12-20 | 2019-09-10 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
CN110418789B (en) | 2017-02-01 | 2022-03-25 | 常州千红生化制药股份有限公司 | Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents |
WO2018162625A1 (en) | 2017-03-09 | 2018-09-13 | Truly Translational Sweden Ab | Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease |
JOP20190209A1 (en) | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
GB201704325D0 (en) | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
CN108864079B (en) | 2017-05-15 | 2021-04-09 | 深圳福沃药业有限公司 | Triazine compound and pharmaceutically acceptable salt thereof |
US11161839B2 (en) | 2017-05-26 | 2021-11-02 | The Institute Of Cancer Research: Royal Cancer Hospital | 2-quinolone derived inhibitors of BCL6 |
WO2018220101A1 (en) | 2017-05-31 | 2018-12-06 | Truly Translational Sweden Ab | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy |
US11400160B2 (en) | 2017-07-05 | 2022-08-02 | E.P.O.S Iasis Research And Development Limited | Multifunctional conjugates |
WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
BR112020001978A2 (en) | 2017-08-01 | 2020-08-18 | Merck Patent Gmbh | thiazolopyridine derivatives as adenosine receptor antagonists |
EP3668882A1 (en) | 2017-08-18 | 2020-06-24 | Cancer Research Technology Limited | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer |
BR112020003594A2 (en) | 2017-08-21 | 2020-09-01 | Merck Patent Gmbh | benzimidazole derivatives as adenosine receptor antagonists |
TW201920123A (en) | 2017-08-21 | 2019-06-01 | 德商馬克專利公司 | Quinoxaline derivatives as adenosine receptor antagonists |
JP7423513B2 (en) | 2017-09-18 | 2024-01-29 | ストロ バイオファーマ インコーポレーテッド | Anti-folate receptor α antibody conjugate and its use |
CN111344293A (en) | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1, 3-dihydroimidazo [4, 5-c ] cinnolin-2-one compounds and their use in the treatment of cancer |
TWI702205B (en) | 2017-10-06 | 2020-08-21 | ***聯邦商拜奧卡德聯合股份公司 | Epidermal growth factor receptor inhibitors |
BR112020009055A2 (en) | 2017-11-06 | 2020-11-03 | Rapt Therapeutics, Inc. | chemokine receptor modulators for positive cancer treatment for epstein-Barr virus |
FI3488868T3 (en) | 2017-11-23 | 2023-10-20 | Medac Ges Fuer Klinische Spezialpraeparate Mbh | Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use |
EP3489222A1 (en) | 2017-11-23 | 2019-05-29 | medac Gesellschaft für klinische Spezialpräparate mbH | Sulfasalazine salts, production processes and uses |
EP3740484A4 (en) | 2018-01-15 | 2021-06-09 | Aucentra Holdings Pty Ltd | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents |
GB201801128D0 (en) | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
CN111971279A (en) | 2018-01-26 | 2020-11-20 | 拉普特医疗公司 | Chemokine receptor modulators and uses thereof |
EP3749310A4 (en) | 2018-02-08 | 2021-08-18 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
ES2939776T3 (en) | 2018-04-13 | 2023-04-26 | Cancer Research Tech Ltd | BCL6 inhibitors |
AU2019260793B2 (en) | 2018-04-27 | 2023-05-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
AR114910A1 (en) | 2018-06-04 | 2020-10-28 | Apros Therapeutics Inc | PYRIMIDINE COMPOUNDS CONTAINING ACID GROUPS |
JP2021527051A (en) | 2018-06-05 | 2021-10-11 | ラプト・セラピューティクス・インコーポレイテッド | Pyrazolo-pyrimidine-amino-cycloalkyl compounds and their therapeutic use |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
EP3852811A1 (en) | 2018-09-17 | 2021-07-28 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
US11084829B2 (en) | 2018-09-24 | 2021-08-10 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof |
CN112912142A (en) | 2018-10-25 | 2021-06-04 | 默克专利股份公司 | 5-azaindazole derivatives as adenosine receptor antagonists |
CN112867715B (en) | 2018-10-25 | 2024-03-05 | 默克专利股份公司 | 5-azaindazole derivatives as adenosine receptor antagonists |
GB201819126D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
EP3960858A4 (en) | 2018-12-25 | 2023-02-15 | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences | Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof |
AR117844A1 (en) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR |
EP3935049A1 (en) | 2019-03-07 | 2022-01-12 | Merck Patent GmbH | Carboxamide-pyrimidine derivatives as shp2 antagonists |
CN111747950B (en) | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | Pyrimidine derivatives for the treatment of cancer |
EP3946618A1 (en) | 2019-04-05 | 2022-02-09 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
WO2020210384A1 (en) | 2019-04-08 | 2020-10-15 | Merck Patent Gmbh | Pyrimidinone derivatives as shp2 antagonists |
GB201905328D0 (en) | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
EA202193049A1 (en) | 2019-05-21 | 2022-02-14 | Вороной Инк. | N-CONTAINING HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING IT AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER |
GB201908885D0 (en) | 2019-06-20 | 2019-08-07 | Storm Therapeutics Ltd | Therapeutic compounds |
CN114728910A (en) | 2019-08-31 | 2022-07-08 | 上海奕拓医药科技有限责任公司 | Pyrazole derivatives for FGFR inhibitor and preparation method thereof |
EP4031249A1 (en) | 2019-09-20 | 2022-07-27 | Ideaya Biosciences, Inc. | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915829D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
CA3162166A1 (en) | 2019-12-02 | 2021-06-10 | Storm Therapeutics Limited | Polyheterocyclic compounds as mettl3 inhibitors |
EP4114852A1 (en) | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
GB202004960D0 (en) | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
GB202012969D0 (en) | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
KR20230074785A (en) * | 2020-09-25 | 2023-05-31 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | Salts of arylaminoquinazoline-containing compounds, preparation methods and applications thereof |
WO2022074379A1 (en) | 2020-10-06 | 2022-04-14 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
WO2022074391A1 (en) | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
CN114948964B (en) * | 2021-02-25 | 2023-10-03 | 石药集团中奇制药技术(石家庄)有限公司 | Use of multi-target protein kinase inhibitors |
GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
EP4329818A1 (en) | 2021-04-30 | 2024-03-06 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
CA3218697A1 (en) | 2021-05-03 | 2022-11-10 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
WO2022245061A1 (en) | 2021-05-17 | 2022-11-24 | 에이치케이이노엔 주식회사 | Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient |
AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
GB202107907D0 (en) | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
WO2023131690A1 (en) | 2022-01-10 | 2023-07-13 | Merck Patent Gmbh | Substituted heterocycles as hset inhibitors |
GB202202199D0 (en) | 2022-02-18 | 2022-04-06 | Cancer Research Tech Ltd | Compounds |
WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023186881A1 (en) | 2022-03-29 | 2023-10-05 | Baden-Württemberg Stiftung Ggmbh | P38 map kinase inhibitors for use in the treatment of colorectal cancer |
GB202204935D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | Nanoparticles |
WO2023196432A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
GB202209404D0 (en) | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024030825A1 (en) | 2022-08-01 | 2024-02-08 | Neupharma, Inc | Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate |
GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213167D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
Citations (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3266990A (en) | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
DE2213558A1 (en) | 1971-03-30 | 1972-10-05 | Lilly Industries Ltd., London | Thiazolyl sulfides |
JPS542327A (en) | 1977-06-07 | 1979-01-09 | Sankyo Co Ltd | Agricultural and horticultural pesticide |
GB2033894A (en) | 1978-09-11 | 1980-05-29 | Sankyo Co | 4-anilinoquinayolines |
US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
GB2160201A (en) | 1984-06-14 | 1985-12-18 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
WO1987004321A2 (en) | 1986-01-23 | 1987-07-30 | Rhone-Poulenc Nederlands B.V. | Use of heterocyclic nitrogen-containing compounds for reducing moisture loss from plants and increasing crop yield |
EP0326330A2 (en) | 1988-01-29 | 1989-08-02 | DowElanco | Quinoline, quinazoline, and cinnoline fungicides |
EP0326307A2 (en) | 1988-01-23 | 1989-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
WO1992014716A1 (en) | 1991-02-20 | 1992-09-03 | Pfizer Inc. | 2,4-diaminoquinazolines derivatives for enhancing antitumor activity |
WO1992016527A1 (en) | 1991-03-22 | 1992-10-01 | Nippon Soda Co., Ltd. | 2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
EP0520722A1 (en) | 1991-06-28 | 1992-12-30 | Zeneca Limited | Therapeutic preparations containing quinazoline derivatives |
EP0566226A1 (en) | 1992-01-20 | 1993-10-20 | Zeneca Limited | Quinazoline derivatives |
EP0602851A1 (en) | 1992-12-10 | 1994-06-22 | Zeneca Limited | Quinazoline derivatives |
US5373011A (en) | 1992-06-11 | 1994-12-13 | American Cyanamid Company | Substituted quinazoline fungicidal agents |
EP0635498A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Quinazoline derivatives and their use as anti-cancer agents |
EP0635507A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclic derivatives and their use as anti-cancer agents |
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
WO1995015758A1 (en) | 1993-12-10 | 1995-06-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase |
WO1995019169A2 (en) | 1994-01-07 | 1995-07-20 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor |
WO1995021613A1 (en) | 1994-02-09 | 1995-08-17 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1995023141A1 (en) | 1994-02-23 | 1995-08-31 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
WO1996009294A1 (en) | 1994-09-19 | 1996-03-28 | The Wellcome Foundation Limited | Substituted heteroaromatic compounds and their use in medicine |
WO1996015118A1 (en) | 1994-11-12 | 1996-05-23 | Zeneca Limited | Aniline derivatives |
WO1996016960A1 (en) | 1994-11-30 | 1996-06-06 | Zeneca Limited | Quinazoline derivatives |
WO1996029331A1 (en) | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
WO1996030370A2 (en) | 1995-03-27 | 1996-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of thrombocytopenia |
WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033977A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033978A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
WO1996033979A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033981A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
US5571815A (en) | 1992-03-14 | 1996-11-05 | Hoechst Aktiengesellschaft | Substituted pyrimidines, process for their preparation, and their use as pesticides and fungicides |
EP0743308A2 (en) | 1995-05-16 | 1996-11-20 | Kanebo, Ltd. | Quinazoline compound and anti-tumor agent containing said compound as an active ingredient |
WO1996039145A1 (en) | 1995-06-06 | 1996-12-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties |
WO1996040673A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Novel urea- and thiourea-type compounds |
WO1996040648A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
WO1997002266A1 (en) | 1995-07-06 | 1997-01-23 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
WO1997003069A1 (en) | 1995-07-13 | 1997-01-30 | Glaxo Group Limited | Heterocyclic compounds and pharmaceutical compositions containing them |
WO1997017329A1 (en) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
WO1997022596A1 (en) | 1995-12-18 | 1997-06-26 | Zeneca Limited | Quinazoline derivatives |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
EP0787722A1 (en) | 1996-02-05 | 1997-08-06 | American Cyanamid Company | Substituted quinazoline derivatives |
WO1997028161A1 (en) | 1996-02-01 | 1997-08-07 | Novartis Ag | Novel pyrrolo[2,3-d]pyrimidines and their use as tyrosine kinase inhibitors |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
WO1997030044A1 (en) | 1996-02-14 | 1997-08-21 | Zeneca Limited | Quinazoline compounds |
WO1997030034A1 (en) | 1996-02-14 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as antitumor agents |
WO1997032856A1 (en) * | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
WO1997037999A1 (en) | 1996-04-04 | 1997-10-16 | University Of Nebraska Board Of Regents | Synthetic triple helix-forming compounds |
DE19614718A1 (en) | 1996-04-15 | 1997-10-16 | Hoechst Schering Agrevo Gmbh | Substituted pyridines / pyrimidines, processes for their preparation and their use as pesticides |
WO1997038983A1 (en) | 1996-04-12 | 1997-10-23 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1997038994A1 (en) | 1996-04-13 | 1997-10-23 | Zeneca Limited | Quinazoline derivatives |
WO1997042187A1 (en) | 1996-05-06 | 1997-11-13 | Zeneca Limited | Oxindole derivatives |
WO1997049689A1 (en) | 1996-06-21 | 1997-12-31 | Pharmacia & Upjohn S.P.A. | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
US5712395A (en) | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
WO1998014431A1 (en) | 1996-10-01 | 1998-04-09 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogenous heterocyclic compounds |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
WO1998023613A1 (en) | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
WO1998010767A3 (en) | 1996-09-13 | 1998-08-06 | Sugen Inc | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
WO1998035958A1 (en) | 1997-02-13 | 1998-08-20 | Novartis Ag | Phthalazines with angiogenesis inhibiting activity |
WO1998043960A1 (en) | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
WO1999006378A1 (en) | 1997-07-29 | 1999-02-11 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1999006396A1 (en) | 1997-07-29 | 1999-02-11 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
WO1999009024A1 (en) | 1997-08-14 | 1999-02-25 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives as hfgan72 antagonists |
WO1999009016A1 (en) | 1997-08-01 | 1999-02-25 | American Cyanamid Company | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
US5929080A (en) | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO2001032651A1 (en) | 1999-11-05 | 2001-05-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
US6414148B1 (en) | 1996-09-25 | 2002-07-02 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US36265A (en) * | 1862-08-26 | Current water-wheel |
-
1997
- 1997-09-09 GB GBGB9718972.4A patent/GB9718972D0/en active Pending
- 1997-09-23 DE DE69717294T patent/DE69717294C5/en not_active Expired - Lifetime
- 1997-09-23 WO PCT/GB1997/002588 patent/WO1998013354A1/en active IP Right Grant
- 1997-09-23 CA CA002263319A patent/CA2263319C/en not_active Expired - Lifetime
- 1997-09-23 US US09/269,595 patent/US6414148B1/en not_active Ceased
- 1997-09-23 AU AU45613/97A patent/AU729968C/en not_active Expired
- 1997-09-23 NZ NZ334014A patent/NZ334014A/en not_active IP Right Cessation
- 1997-09-23 CN CNB971981337A patent/CN1142920C/en not_active Expired - Lifetime
- 1997-09-23 UA UA99042295A patent/UA57752C2/en unknown
- 1997-09-23 SI SI9730461T patent/SI0929530T1/en unknown
- 1997-09-23 AT AT97943954T patent/ATE228114T1/en active IP Right Maintenance
- 1997-09-23 BR BRPI9711302-6A patent/BR9711302B1/en not_active IP Right Cessation
- 1997-09-23 CZ CZ0103999A patent/CZ296962B6/en not_active IP Right Cessation
- 1997-09-23 RU RU99108663/04A patent/RU2198879C2/en active Protection Beyond IP Right Term
- 1997-09-23 HU HU9902850A patent/HU228176B1/en unknown
- 1997-09-23 TR TR1999/00674T patent/TR199900674T2/en unknown
- 1997-09-23 PL PL97332385A patent/PL190326B1/en unknown
- 1997-09-23 SK SK389-99A patent/SK283175B6/en not_active IP Right Cessation
- 1997-09-23 KR KR1019997002499A patent/KR100618065B1/en active Protection Beyond IP Right Term
- 1997-09-23 JP JP51538798A patent/JP3438818B2/en not_active Expired - Fee Related
- 1997-09-23 IL IL12903897A patent/IL129038A/en not_active IP Right Cessation
- 1997-09-23 ES ES97943954T patent/ES2185999T3/en not_active Expired - Lifetime
- 1997-09-23 ZA ZA9708553A patent/ZA978553B/en unknown
- 1997-09-23 US US12/170,027 patent/USRE42353E1/en not_active Expired - Lifetime
- 1997-09-23 PT PT97943954T patent/PT929530E/en unknown
- 1997-09-23 EP EP97943954A patent/EP0929530B1/en not_active Expired - Lifetime
- 1997-09-23 CH CH97943954T patent/CH0929530H1/de unknown
- 1997-09-23 DK DK97943954T patent/DK0929530T3/en active
- 1997-09-24 MY MYPI97004436A patent/MY129540A/en unknown
- 1997-09-24 TW TW086113896A patent/TW520364B/en not_active IP Right Cessation
-
1999
- 1999-03-24 NO NO991422A patent/NO313138B1/en not_active IP Right Cessation
- 1999-09-22 HK HK99104114A patent/HK1019332A1/en not_active IP Right Cessation
-
2002
- 2002-02-25 US US10/080,716 patent/US6673803B2/en not_active Expired - Lifetime
-
2003
- 2003-03-20 JP JP2003120734A patent/JP2004002406A/en not_active Withdrawn
- 2003-03-20 JP JP2003079216A patent/JP2003238539A/en active Pending
- 2003-11-03 US US10/698,388 patent/US6897210B2/en not_active Expired - Lifetime
-
2004
- 2004-05-17 CY CY0400038A patent/CY2453B1/en unknown
- 2004-05-20 CL CL200401178A patent/CL2004001178A1/en unknown
- 2004-12-30 US US11/024,840 patent/US20050239777A1/en not_active Abandoned
-
2010
- 2010-04-23 US US12/766,106 patent/US20110071144A1/en not_active Abandoned
Patent Citations (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3266990A (en) | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
DE2213558A1 (en) | 1971-03-30 | 1972-10-05 | Lilly Industries Ltd., London | Thiazolyl sulfides |
JPS542327A (en) | 1977-06-07 | 1979-01-09 | Sankyo Co Ltd | Agricultural and horticultural pesticide |
GB2033894A (en) | 1978-09-11 | 1980-05-29 | Sankyo Co | 4-anilinoquinayolines |
US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
GB2160201A (en) | 1984-06-14 | 1985-12-18 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
WO1987004321A2 (en) | 1986-01-23 | 1987-07-30 | Rhone-Poulenc Nederlands B.V. | Use of heterocyclic nitrogen-containing compounds for reducing moisture loss from plants and increasing crop yield |
EP0326307A2 (en) | 1988-01-23 | 1989-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
EP0326330A2 (en) | 1988-01-29 | 1989-08-02 | DowElanco | Quinoline, quinazoline, and cinnoline fungicides |
WO1992014716A1 (en) | 1991-02-20 | 1992-09-03 | Pfizer Inc. | 2,4-diaminoquinazolines derivatives for enhancing antitumor activity |
WO1992016527A1 (en) | 1991-03-22 | 1992-10-01 | Nippon Soda Co., Ltd. | 2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
USRE36256E (en) | 1991-05-10 | 1999-07-20 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5646153A (en) | 1991-05-10 | 1997-07-08 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6057320A (en) | 1991-05-10 | 2000-05-02 | Aventis Pharmaceuticals Products Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP0520722A1 (en) | 1991-06-28 | 1992-12-30 | Zeneca Limited | Therapeutic preparations containing quinazoline derivatives |
US5457105A (en) | 1992-01-20 | 1995-10-10 | Zeneca Limited | Quinazoline derivatives useful for treatment of neoplastic disease |
EP0566226A1 (en) | 1992-01-20 | 1993-10-20 | Zeneca Limited | Quinazoline derivatives |
US5616582A (en) | 1992-01-20 | 1997-04-01 | Zeneca Limited | Quinazoline derivatives as anti-proliferative agents |
US5571815A (en) | 1992-03-14 | 1996-11-05 | Hoechst Aktiengesellschaft | Substituted pyrimidines, process for their preparation, and their use as pesticides and fungicides |
US5373011A (en) | 1992-06-11 | 1994-12-13 | American Cyanamid Company | Substituted quinazoline fungicidal agents |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5712395A (en) | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5580870A (en) | 1992-12-10 | 1996-12-03 | Zeneca Limited | Quinazoline derivatives |
EP0602851A1 (en) | 1992-12-10 | 1994-06-22 | Zeneca Limited | Quinazoline derivatives |
US5475001A (en) | 1993-07-19 | 1995-12-12 | Zeneca Limited | Quinazoline derivatives |
EP0635507A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclic derivatives and their use as anti-cancer agents |
EP0635498A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Quinazoline derivatives and their use as anti-cancer agents |
US5569658A (en) | 1993-07-19 | 1996-10-29 | Zeneca Limited | Tricyclic derivatives |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
WO1995015758A1 (en) | 1993-12-10 | 1995-06-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase |
WO1995019169A2 (en) | 1994-01-07 | 1995-07-20 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor |
WO1995021613A1 (en) | 1994-02-09 | 1995-08-17 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5736534A (en) | 1994-02-23 | 1998-04-07 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
WO1995023141A1 (en) | 1994-02-23 | 1995-08-31 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
WO1996009294A1 (en) | 1994-09-19 | 1996-03-28 | The Wellcome Foundation Limited | Substituted heteroaromatic compounds and their use in medicine |
WO1996015118A1 (en) | 1994-11-12 | 1996-05-23 | Zeneca Limited | Aniline derivatives |
US5821246A (en) | 1994-11-12 | 1998-10-13 | Zeneca Limited | Aniline derivatives |
WO1996016960A1 (en) | 1994-11-30 | 1996-06-06 | Zeneca Limited | Quinazoline derivatives |
US5955464A (en) | 1994-11-30 | 1999-09-21 | Zeneca Limited | 4-anilinoquinazoline derivatives bearing a heteroaryl substituted at the 6-position and possessing anti-cell-proliferation properties |
WO1996029331A1 (en) | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
WO1996030370A2 (en) | 1995-03-27 | 1996-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of thrombocytopenia |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
US6015814A (en) | 1995-04-27 | 2000-01-18 | Zeneca Limited | Quinazoline derivative |
WO1996033981A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
US5942514A (en) | 1995-04-27 | 1999-08-24 | Zeneca Limited | Quinazoline derivatives |
WO1996033979A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033978A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
WO1996033977A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
US5952333A (en) | 1995-04-27 | 1999-09-14 | Zeneca Limited | Quinazoline derivative |
US5932574A (en) | 1995-04-27 | 1999-08-03 | Zeneca Limited | Quinazoline derivatives |
US5770599A (en) | 1995-04-27 | 1998-06-23 | Zeneca Limited | Quinazoline derivatives |
EP0743308A2 (en) | 1995-05-16 | 1996-11-20 | Kanebo, Ltd. | Quinazoline compound and anti-tumor agent containing said compound as an active ingredient |
WO1996039145A1 (en) | 1995-06-06 | 1996-12-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties |
WO1996040648A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
WO1996040673A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Novel urea- and thiourea-type compounds |
WO1997002266A1 (en) | 1995-07-06 | 1997-01-23 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
WO1997003069A1 (en) | 1995-07-13 | 1997-01-30 | Glaxo Group Limited | Heterocyclic compounds and pharmaceutical compositions containing them |
WO1997017329A1 (en) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
US6258951B1 (en) | 1995-12-18 | 2001-07-10 | Zeneca Limited | Chemical compounds |
US6362336B1 (en) | 1995-12-18 | 2002-03-26 | Zeneca Limited | Chemical compounds |
US6071921A (en) | 1995-12-18 | 2000-06-06 | Zeneca Limited | Chemical compounds |
WO1997022596A1 (en) | 1995-12-18 | 1997-06-26 | Zeneca Limited | Quinazoline derivatives |
US5962458A (en) | 1995-12-18 | 1999-10-05 | Zeneca Limited | Substituted quinazolines |
WO1997028161A1 (en) | 1996-02-01 | 1997-08-07 | Novartis Ag | Novel pyrrolo[2,3-d]pyrimidines and their use as tyrosine kinase inhibitors |
EP0787722A1 (en) | 1996-02-05 | 1997-08-06 | American Cyanamid Company | Substituted quinazoline derivatives |
WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
US6897214B2 (en) | 1996-02-14 | 2005-05-24 | Zeneca Limited | Quinazoline derivatives |
WO1997030044A1 (en) | 1996-02-14 | 1997-08-21 | Zeneca Limited | Quinazoline compounds |
WO1997030034A1 (en) | 1996-02-14 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as antitumor agents |
US6399602B1 (en) | 1996-02-14 | 2002-06-04 | Zeneca Limited | Quinazoline derivatives |
US5814630A (en) | 1996-02-14 | 1998-09-29 | Zeneca Limited | Quinazoline compounds |
US5866572A (en) | 1996-02-14 | 1999-02-02 | Zeneca Limited | Quinazoline derivatives |
WO1997032856A1 (en) * | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
US7087602B2 (en) | 1996-03-15 | 2006-08-08 | Astrazeneca Uk Limited | Cinnoline derivatives and use as medicine |
US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
WO1997037999A1 (en) | 1996-04-04 | 1997-10-16 | University Of Nebraska Board Of Regents | Synthetic triple helix-forming compounds |
WO1997038983A1 (en) | 1996-04-12 | 1997-10-23 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
US5770603A (en) | 1996-04-13 | 1998-06-23 | Zeneca Limited | Quinazoline derivatives |
WO1997038994A1 (en) | 1996-04-13 | 1997-10-23 | Zeneca Limited | Quinazoline derivatives |
DE19614718A1 (en) | 1996-04-15 | 1997-10-16 | Hoechst Schering Agrevo Gmbh | Substituted pyridines / pyrimidines, processes for their preparation and their use as pesticides |
US6265411B1 (en) | 1996-05-06 | 2001-07-24 | Zeneca Limited | Oxindole derivatives |
WO1997042187A1 (en) | 1996-05-06 | 1997-11-13 | Zeneca Limited | Oxindole derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
WO1997049689A1 (en) | 1996-06-21 | 1997-12-31 | Pharmacia & Upjohn S.P.A. | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
WO1998010767A3 (en) | 1996-09-13 | 1998-08-06 | Sugen Inc | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
US6809097B1 (en) | 1996-09-25 | 2004-10-26 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
US6414148B1 (en) | 1996-09-25 | 2002-07-02 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
US20050239777A1 (en) | 1996-09-25 | 2005-10-27 | Thomas Andrew P | Quinazoline derivatives and pharmaceutical compositions containing them |
WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
US6897210B2 (en) | 1996-09-25 | 2005-05-24 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
US6673803B2 (en) | 1996-09-25 | 2004-01-06 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
WO1998014431A1 (en) | 1996-10-01 | 1998-04-09 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogenous heterocyclic compounds |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
WO1998023613A1 (en) | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
WO1998035958A1 (en) | 1997-02-13 | 1998-08-20 | Novartis Ag | Phthalazines with angiogenesis inhibiting activity |
WO1998043960A1 (en) | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
US5929080A (en) | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
WO1999006396A1 (en) | 1997-07-29 | 1999-02-11 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
WO1999006378A1 (en) | 1997-07-29 | 1999-02-11 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1999009016A1 (en) | 1997-08-01 | 1999-02-25 | American Cyanamid Company | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
WO1999009024A1 (en) | 1997-08-14 | 1999-02-25 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives as hfgan72 antagonists |
WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
WO2001032651A1 (en) | 1999-11-05 | 2001-05-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
US7173038B1 (en) | 1999-11-05 | 2007-02-06 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
US20070265286A1 (en) | 1999-11-05 | 2007-11-15 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
Non-Patent Citations (38)
Title |
---|
Arya et al., Nitroimidazoles: Part XVI-Some 1-Methy1-4-nitro-5-substituted Imidazoles, Indian Journal of Chemistry, vol. 21B, Dec. 1982, pp. 1115-1117. |
Bridges, "The current status of tyrosine kinase inhibitors . . . ," Exp.Opin.Ther.Patents (1995), 5(12): 1245-1257, Editorial, Oncologic, Endocrine & Metabolic, 1995 Ashley Publications Ltd ISSN 1354-3776. |
Bridges, et al., "Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by 4-(a-Phenethylamino)quinazolines," Bioorganic & Medicinal Chemistry, vol. 3, No. 12, pp. 1651-1656, 1995. |
Connolly, et al., "Human Vascular Permeability Factor," J.Bio.Chem., vol. 264, No. 33, Nov. 1989, pp. 20017-20024. |
Cullinan-Bove, et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor Expression in the Rat Uterus . . . ," Endocrinology, vol. 133, No. 2, 1993, pp. 829-837. |
Fan, et al., "Controlling the Vasculature: Angiogenesis, Anti-Angiogenesis . . . ," TiPS Review, vol. 16, Feb. 1995, pp. 57-66. |
Folkman, "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease," Nature Medicine, vol. 1, No. 1, 1995, pp. 27-31. |
Fry et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," Science, vol. 265, Aug. 19, 1994, pp. 1093-1095. |
Gazit et al., Tyrophostins IV-Highly Potent Inhibitors . . . Relationship Study of 4-Anilidoquinazolines, Bioorganic & Medicinal Chemistry, vol. 4. No. 8, 1996, pp. 1203-1207. |
Golovkin et al., Nauchin TR-VSES-NAUCHNO-ISSLED INST FARM, 1990, 28, 70-75. |
Hara et al., On the Amination of Azaheterocycles. A New Procedure for the Introduction of an Amino Group (1), J. Heterocyclic Chem. vol. 19, 1982, pp. 1285-1287. |
Higashino et al., "Reactions of the Anion of Quinazoline Reissert Compound (3-Benzoyl-3,4-dihydro-4-quinazolinecarbonitrile) with Electrophiles", Chem. Phar. Bull. 33(3), 1985, pp. 950-961. |
Iyer, et al., "Studies in Potential Amoebicides: Part III-Synthesis of 4-Substituted Amino-8-Hydroxy) Quinazolines & 3-Substituted 8-Hydroxy(&8-Methoxy)-4-Quinazolones," J.Sci.Industr.Res., vol. 15C, Jan. 1956, pp. 1-7. |
Iyer, et. al.; Journal of Scientific & Industrial Research (1954), 13B, 451-2. * |
Jakeman, et al., "Developmental Expression of Binding Sites and Messenger Ribonucleic Acid . . . ," Endocrinology, vol. 133, No. 2, 1993, pp. 848-859. |
Karminski et al., The Synthesis of Some Quinazoline Derivatives and Their Biological Properties; J. Environ. Sci. Health, vol. B18, 1983, pp. 599-610. |
Kim, et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in Vivo," Nature, vol. 362, Apr. 1993, pp. 841-844. |
Klohs et al., "Antiangiognenic Agents", Curr. Opin. Biotech, 1/6, 1999, 544-549 (Abstract Attached). |
Klohs, Wayne D. et."Antiangiogenic Agts.",Curr.Opin.Biotech. 10/6.544-49, Jun. 1999. * |
Kobayashi, Derwent Abstract 82-87077, vol. 6, No. 244, Dec. 1982, JP 57-144266, Sep. 1982, "4-Anilinoquinazoline Derivative, its Preparation and Analgesic and Antiphlogistic Agent Containing Said Derivative as Active Component". (n. 7). |
Kolch, et al., "Regulation of the Expression of the VEGF/VPS and its Receptors: Role in Tumor Angiogenesis," Breast Cancer Research and Treatment, vol. 36, 1995, pp. 139-155. |
Kumar et al., Reactions of Diazines with Nucleophiles-IV.1 The Reactivity . . Single Electron Transfer Reactions, Bioorganic & Medicinal Chemistry, vol. 3, No. 7, 1995, pp. 891-897. |
Kyorin, Derwent Abstract 84-53835, JP 59-13765, Jan. 1984, "2-(4-Quinazolinyl)amino benzoic acid derivs . . . having analgesic and antiinflammatory activities". (n.8). |
Li, et al., Chem.Abs., vol. 92:76445u, 1980, p. 674-675. |
Lin et al., Chem.Abs., vol. 96:122728w, 1982, p. 695. |
Nagarajan et al., Nitroimidazoles: Part XIX†-Structure Activity Relationships‡, Indian Journal of Chemistry, vol. 23B, Apr. 1984, pp. 342-362. |
Nomoto et al., Studies on Cardiotonic Agents. VII.1) Potent Cardiotonic Agent KF15232 with Myofibrillar CA2+ Sensitizing Effect, Chem. Pharm. Bull., vol. 39(4), 1991, pp. 900-910. |
Rewcastle et al., "Tyrosine Kinase Inhibitors. 5 . . . 4-(Phenylamino)quinazolines as Potent . . . Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor," J.Med.Chem. 1995, vol. 38, pp. 3482-3487. |
Sankyo and Ube, Derwent Abstract 81-28290, JP 56-20577, Feb. 1981, "4-(N-alkyl:anilino) quinazoline derivs . . . having analgesic and antiinflammatory actions". (n.9). |
Schonowsky et al., Chinazolinderivate, ihre Herstellung und biologische Wirkung, Quinzaolines, their Preparation and Biological Activity, Z. Naturforsch, 37b, 1982, pp. 907-911. |
Senger, et al., "Vascular Permeability Factor (VPF, VEGF) in Tumor Biology," Cancer and Metastasis Reviews, vol. 12, 1993, pp. 303-324. |
Sinyak, et al., Synthesis and Biological Properties of Derivatives of 4-Heterylmercaptoquinazoline, Zaporozh'e Medical Institute pp. 103-106, translated from Khimiko-farmatsevticheskii Zhurnal, vol. 20, No. 2, Feb. 1986, 168-171, original article submitted Dec. 29, 1984. |
Spada, et al., Small molecule inhibitors of tyrosine Kinase activity, Exp.Opin.Ther.Patents (1995), 5(8):805-817, Patent Update, Oncologic, Endocrine & Metabolic, Ashley Publications Ltd ISSN 1354-3776. |
Stets et al., Investigation of Anti-Arrhythmic Action of Quinazopyrine, Pharmacology Dept., Zaporozhye Medical Institute, Zaporozhye, and Vinnitsa Medical Institute, Vinnitsa, pp. 94-96, translated from Farmakol. 1 toksik., vol. 53, No. 3, 1990, pp. 15-17. |
Traxler, et al., "Recent advances in protein tyrosine kinase inhibitors," Drugs of the Future 1995, vol. 20(12, pp. 1261-1274. |
Vinogradoff et a;/, Development of a New Synthesis of . . . Sodium Salt via an Amidine Intermediate. J. Heterocyclic Chem. vol. 26, 97, Jan.-Feb. 1989, pp. 97-103. |
Ward, et al., "Epidermal Growth Factor Receptor Tyrosine Kinase-Investigation of Catalytic Mechanism, Structure-Based Searching and Discovery of a Potent Inhibitor," Biochem.Pharmacology, vol. 48, No. 4, pp. 659-666 (1994). |
Wolfe et al., A Facile One-Step Synthesis of Certain 4-(4-Pyrimidinylmethyl)quinazolines, J. Heterocyclic Chem., vol. 13, 1976, pp. 383-385. |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10457664B2 (en) | 1999-11-05 | 2019-10-29 | Genzyme Corporation | Quinazoline derivatives as VEGF inhibitors |
US9040548B2 (en) | 1999-11-05 | 2015-05-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
US8772272B2 (en) | 2003-12-18 | 2014-07-08 | Janssen Pharmaceutica Nv | Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents |
US20100173913A1 (en) * | 2003-12-18 | 2010-07-08 | Janssen Pharmaceutica N.V. | Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents |
US8933067B2 (en) | 2003-12-18 | 2015-01-13 | Janssen Pharmaceutica Nv | Pyrido and pyrimidopyrimidine derivatives as anti-profilerative agents |
US9688691B2 (en) | 2004-12-08 | 2017-06-27 | Janssen Pharmaceutica Nv | Macrocyclic quinazole derivatives and their use as MTKI |
US10208062B2 (en) | 2004-12-08 | 2019-02-19 | Janssen Pharmaceutica Nv | Macrocyclic quinazole derivatives and their use as MTKI |
US20100152174A1 (en) * | 2004-12-08 | 2010-06-17 | Eddy Jean Edgard Freyne | Macrocyclic quinazole derivatives and their use as mtki |
US20100029627A1 (en) * | 2006-07-12 | 2010-02-04 | Alexandra Papanikos | Mtki quinazoline derivatives |
US8492377B2 (en) | 2006-07-13 | 2013-07-23 | Janssen Pharmaceutica Nv | MTKI quinazoline derivatives |
US8318731B2 (en) | 2007-07-27 | 2012-11-27 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
WO2015031604A1 (en) | 2013-08-28 | 2015-03-05 | Crown Bioscience, Inc. | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
US10011587B2 (en) | 2014-05-15 | 2018-07-03 | The Methodist Hospital System | Multivalent ligands targeting VEGFR |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE42353E1 (en) | Quinazoline derivatives and pharmaceutical compositions containing them | |
US10457664B2 (en) | Quinazoline derivatives as VEGF inhibitors | |
US6184225B1 (en) | Quinazoline derivatives as VEGF inhibitors | |
EP0885198B1 (en) | 4-anilinoquinazoline derivatives | |
US6265411B1 (en) | Oxindole derivatives | |
US7087602B2 (en) | Cinnoline derivatives and use as medicine | |
US7262201B1 (en) | Quinazoline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: CAPRELSA (VANDETANIB); REQUESTED FOR 1738 DAYS Filing date: 20110601 Expiry date: 20170923 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: ZENECA PHARMA S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THOMAS, ANDREW PETER;JOHNSTON, CRAIG;CLAYTON, EDWARD;AND OTHERS;SIGNING DATES FROM 19990215 TO 19990315;REEL/FRAME:035550/0475 Owner name: ZENECA LIMITED, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THOMAS, ANDREW PETER;JOHNSTON, CRAIG;CLAYTON, EDWARD;AND OTHERS;SIGNING DATES FROM 19990215 TO 19990315;REEL/FRAME:035550/0475 Owner name: ASTRAZENECA UK LIMITED, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZENECA LIMITED (NOW SYNGENTA LIMITED);REEL/FRAME:035550/0515 Effective date: 20000104 Owner name: ASTRAZENECA UK LIMITED, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA SAS;REEL/FRAME:035550/0633 Effective date: 20050621 Owner name: ASTRAZENECA SAS, FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:ZENECA PHARMA SA;REEL/FRAME:035561/0331 Effective date: 20000207 Owner name: SYNGENTA LIMITED, ENGLAND Free format text: CHANGE OF NAME;ASSIGNOR:ZENECA LIMITED;REEL/FRAME:035567/0259 Effective date: 20020527 |
|
AS | Assignment |
Owner name: ZENECA PHARMA S.A., FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND ASSIGNOR NAME FROM CRAIG JOHNSTON TO CRAIG JOHNSTONE PREVIOUSLY RECORDED ON REEL 035550 FRAME 0475. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THOMAS, ANDREW PETER;JOHNSTONE, CRAIG;CLAYTON, EDWARD;AND OTHERS;SIGNING DATES FROM 19990215 TO 19990315;REEL/FRAME:035602/0634 Owner name: ZENECA LIMITED, ENGLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND ASSIGNOR NAME FROM CRAIG JOHNSTON TO CRAIG JOHNSTONE PREVIOUSLY RECORDED ON REEL 035550 FRAME 0475. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THOMAS, ANDREW PETER;JOHNSTONE, CRAIG;CLAYTON, EDWARD;AND OTHERS;SIGNING DATES FROM 19990215 TO 19990315;REEL/FRAME:035602/0634 |
|
AS | Assignment |
Owner name: GENZYME CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA UK LIMITED;REEL/FRAME:038319/0509 Effective date: 20150930 |
|
PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: CAPRELSA (VANDETANIB) Filing date: 20110601 Expiry date: 20170923 |
|
CC | Certificate of correction | ||
CC | Certificate of correction |